: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

The Angels Initiative

Stroke prevention

Gynecology

Free Subscription

Articles published in Gynecol Oncol
Retrieve available abstracts of 644 articles:
HTML format

Single Articles

September 2023

WHELAN K, Dillon M, Strickland KC, Pothuri B, et al
TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
Gynecol Oncol. 2023;178:44-53.
PubMed Abstract available

KOBAYASHI-KATO M, Fujii E, Asami Y, Ahiko Y, et al
Utility of the revised FIGO2023 staging with molecular classification in endometrial cancer.
Gynecol Oncol. 2023;178:36-43.
PubMed Abstract available

ZAMMARRELLI WA 3RD, Ma W, Espino K, Gordhandas S, et al
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Gynecol Oncol. 2023;178:27-35.
PubMed Abstract available

BOITANO TKL, Gardner A, Chu DI, Leath CA 3rd, et al
Use of a mobile health patient engagement technology improves perioperative outcomes in gynecologic oncology patients.
Gynecol Oncol. 2023;178:23-26.
PubMed Abstract available

HAIGHT PJ, Kistenfeger Q, Riedinger CJ, Khadraoui W, et al
The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
Gynecol Oncol. 2023;178:14-22.
PubMed Abstract available

BLACK KA, Nelson G, Goucher N, Foley J, et al
Effect of transversus abdominis plane block on postoperative outcomes in gynecologic oncology patients managed on an Enhanced Recovery After Surgery pathway.
Gynecol Oncol. 2023;178:1-7.
PubMed Abstract available

MARSH LA, Kim TH, Zhang M, Kubalanza K, et al
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
Gynecol Oncol. 2023;177:173-179.
PubMed Abstract available

WRIGHT AA, Poort H, Tavormina A, Schmiege SJ, et al
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
Gynecol Oncol. 2023;177:165-172.
PubMed Abstract available

AGUSTI N, Viveros-Carreno D, Mora-Soto N, Ramirez PT, et al
Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;177:157-164.
PubMed Abstract available

HUI C, Mendoza MG, von Eyben R, Dorigo O, et al
Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?
Gynecol Oncol. 2023;177:150-156.
PubMed Abstract available

LEE HC, Jeong JW, Lee JH, Kim SH, et al
High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial.
Gynecol Oncol. 2023;177:142-149.
PubMed Abstract available

TOBONI MD, Wu S, Farrell A, Xiu J, et al
Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.
Gynecol Oncol. 2023;177:132-141.
PubMed Abstract available

DUUS AH, Zheng G, Baandrup L, Faber MT, et al
Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on histology and time since the procedure.
Gynecol Oncol. 2023;177:125-131.
PubMed Abstract available

MOUFARRIJ S, Havrilesky L, Jewell EL
Universal thromboprophylaxis in ovarian cancer patients before and after surgery?
Gynecol Oncol. 2023;176:A1-A2.
PubMed

BRUCE KH, Alabaster A, Tran AM
Vulvar cancer survival by primary treatment modality: A retrospective cohort study.
Gynecol Oncol. 2023;176:173-178.
PubMed Abstract available

PRAISS AM, Allison D, Tessier-Cloutier B, Flynn J, et al
Extensive versus focal lymphovascular invasion in squamous cell carcinoma of the cervix: A comprehensive international, multicenter, retrospective clinicopathologic study.
Gynecol Oncol. 2023;176:147-154.
PubMed Abstract available

MCGONIGAL S, Wu R, Grimley E, Turk EG, et al
A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
Gynecol Oncol. 2023;176:139-146.
PubMed Abstract available

LIU Y, Chen J, Lu Z, Chang X, et al
Clinicopathological analysis of patients with molecularly confirmed stage I adult granulosa cell tumors and prediction of recurrence.
Gynecol Oncol. 2023;176:106-114.
PubMed Abstract available

LIM H, Ju Y, Kim SI, Park JH, et al
Clinical implications of histologic subtypes on survival outcomes in primary mucinous ovarian carcinoma.
Gynecol Oncol. 2023;177:117-124.
PubMed Abstract available

SPAGNOL G, Marchetti M, De Tommasi O, Vitagliano A, et al
Simple rules, O-RADS, ADNEX and SRR model: Single oncologic center validation of diagnostic predictive models alone and combined (two-step strategy) to estimate the risk of malignancy in adnexal masses and ovarian tumors.
Gynecol Oncol. 2023;177:109-116.
PubMed Abstract available

August 2023

ANDRIANI L, Oh J, McMinn E, Gleason E, et al
Telehealth utilization in gynecologic oncology clinical trials.
Gynecol Oncol. 2023;177:103-108.
PubMed Abstract available

NASIOUDIS D, Fernandez ML, Wong N, Powell DJ Jr, et al
The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
Gynecol Oncol. 2023;177:86-94.
PubMed Abstract available

NARAYAN P, Ahsan MD, Webster EM, Perez L, et al
Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;177:72-85.
PubMed Abstract available

BLITZER GC, Zhao SG, Bradley KA, Hartenbach EM, et al
The role of ctDNA in endometrial cancer: A tool for risk stratification and disease monitoring.
Gynecol Oncol. 2023 Aug 28:S0090-8258(23)01437.
PubMed

AO W, Kim HI, Tommarello D, Conrads KA, et al
Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
Gynecol Oncol. 2023;177:60-71.
PubMed Abstract available

MARJON N, Guerra R, Freeman A, Mak J, et al
Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer.
Gynecol Oncol. 2023;177:53-59.
PubMed Abstract available

MORTON M, McLaughlin EM, Calo CA, Lightfoot M, et al
Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?
Gynecol Oncol. 2023;177:46-52.
PubMed Abstract available

HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
Gynecol Oncol. 2023;177:38-45.
PubMed Abstract available

KIM JH, Park KN, Park EY, Jang MJ, et al
Impact of warm saline irrigation, hyperthermic intraperitoneal chemotherapy on postoperative pain in primary ovarian cancer from the KOV-HIPEC-01 randomized trial.
Gynecol Oncol. 2023;177:32-37.
PubMed Abstract available

PIGNATA S, Bookman M, Sehouli J, Miller A, et al
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Gynecol Oncol. 2023;177:20-31.
PubMed Abstract available

NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
Gynecol Oncol. 2023;177:14-19.
PubMed Abstract available

HOLTZMAN S, Wang K, Saleh M, Papatla K, et al
Letters of recommendation for gynecologic oncology fellowship differ by gender and race.
Gynecol Oncol. 2023;177:9-13.
PubMed Abstract available

WONG NKY, Llaurado Fernandez M, Kommoss FKF, Praveen Kumar P, et al
Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.
Gynecol Oncol. 2023;176:162-172.
PubMed Abstract available

KOROMPELIS P, Rundle S, Cassar V, Ratnavelu N, et al
"Conservative surgical approaches for small volume FIGO stage IB1 cervical cancer. Updated survival and obstetric outcomes of an expanded cohort".
Gynecol Oncol. 2023;176:155-161.
PubMed Abstract available

LEUNG E, Tremblay C, Liao D, Burnett M, et al
Treatment patterns and outcomes of patients with locally advanced vulvar or vaginal cancer in British Columbia.
Gynecol Oncol. 2023;175:107-113.
PubMed Abstract available

JAMIESON A, McConechy MK, Lum A, Leung S, et al
Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.
Gynecol Oncol. 2023;175:45-52.
PubMed Abstract available

GARRETT AA, Ricciuti J, Lang SM, Burriss ME, et al
Feasibility of intraoperative injection of radioactive tracer and blue dye for sentinel lymph node biopsy in vulvar cancer.
Gynecol Oncol. 2023;175:41-44.
PubMed Abstract available

TAYLOR DD, Gercel-Taylor C, Parker LP
Retraction notice to "Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology Volume 115, Issue 1, October 2009, Pages 112-120].
Gynecol Oncol. 2023;175:193.
PubMed

TAYLOR DD, Gercel-Taylor C
Retraction notice to "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer" [Gynecologic Oncology, Volume 110, Issue 1, July 2008, Pages 13-21].
Gynecol Oncol. 2023;175:192.
PubMed

July 2023

BRAGA A, Lopes R, Campos V, Freitas F, et al
The impact of the distance traveled between residence and gestational trophoblastic neoplasia reference center and clinical outcomes in Brazilian women.
Gynecol Oncol. 2023;176:130-138.
PubMed Abstract available

KONG TW, Kim J, Son JH, Lee AJ, et al
Is minimally invasive radical surgery safe for patients with cervical cancer
Gynecol Oncol. 2023;176:122-129.
PubMed Abstract available

SAITO A, Nishikawa T, Yoshida H, Mizoguchi C, et al
Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Gynecol Oncol. 2023;176:115-121.
PubMed Abstract available

MERCADEL AJ, Sanchez-Covarrubias AP, Medina HN, Pinheiro PS, et al
Intra-racial disaggregation reveals associations between nativity and overall survival in women with endometrial cancer.
Gynecol Oncol. 2023;176:98-105.
PubMed Abstract available

HORVAT N, Causa Andrieu P, Meier A, Ji X, et al
A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma.
Gynecol Oncol. 2023;176:90-97.
PubMed Abstract available

KIKUCHI A, Yoshida H, Tsuda H, Nishio S, et al
Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study from the Japanese Clinical Oncology Group.
Gynecol Oncol. 2023;176:82-89.
PubMed Abstract available

DOS SANTOS MV, Holth A, Lindemann K, Staff AC, et al
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
Gynecol Oncol. 2023;176:76-81.
PubMed Abstract available

SIA TY, Manning-Geist BL, Ehmann S, Lavery JA, et al
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2023;176:69-75.
PubMed Abstract available

EIDE AJ, Halle MK, Lura N, Fasmer KE, et al
Visceral fat percentage for prediction of outcome in uterine cervical cancer.
Gynecol Oncol. 2023;176:62-68.
PubMed Abstract available

MOREIRA I, Ferreira M, Garcia S, Novais P, et al
Practical lessons learned from real-world implementation of the molecular classification for endometrial carcinoma.
Gynecol Oncol. 2023;176:53-61.
PubMed Abstract available

ZHANG Y, Chu R, Zhang Z, Xu C, et al
Prognostic significance of positive peritoneal cytology in endometrial carcinoma based on ESGO/ESTRO/ESP risk classification: A multicenter retrospective study.
Gynecol Oncol. 2023;176:43-52.
PubMed Abstract available

SHAFA A, Watkins AB, McGree ME, Weroha SJ, et al
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Gynecol Oncol. 2023;176:36-42.
PubMed Abstract available

ESPANOL P, Rovira R, Caruana P, Luna-Guibourg R, et al
Dopamine receptors D1 and D2 show prognostic significance and potential therapeutic applications for endometrial cancer patients.
Gynecol Oncol. 2023;176:25-35.
PubMed Abstract available

O'CEARBHAILL RE, Miller A, Soslow RA, Lankes HA, et al
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
Gynecol Oncol. 2023;176:16-24.
PubMed Abstract available

KAHVECIOGLU A, Gurlek E, Yedekci FY, Sari SY, et al
Simultaneous integrated or sequential boost to clinically involved lymph nodes in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy.
Gynecol Oncol. 2023;176:10-15.
PubMed Abstract available

GE J, Fader AN, Dudley JC
Early detection of endometrial cancer.
Gynecol Oncol. 2023;174:A1-A2.
PubMed

June 2023

KONSKI A, Deshmukh S, Klopp AH, Yeung AR, et al
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203.
Gynecol Oncol. 2023;175:176-181.
PubMed Abstract available

BURKETT WC, Iwai Y, Gehrig PA, Knittel AK, et al
Fractured and delayed: A qualitative analysis of disruptions in care for gynecologic malignancies during incarceration.
Gynecol Oncol. 2023;176:1-9.
PubMed Abstract available

MAH SJ, Carter Ramirez DM, Eiriksson LR, Schnarr K, et al
Palliative care utilization across health sectors for patients with gynecologic malignancies in Ontario, Canada from 2006 to 2018.
Gynecol Oncol. 2023;175:169-175.
PubMed Abstract available

TAYLOR KN, Li A, Manuel M, Rimel BJ, et al
The association of black race with receipt of hysterectomy and survival in low-risk endometrial cancer.
Gynecol Oncol. 2023;175:156-162.
PubMed Abstract available

FEINBERG J, Zivanovic O, Hannon M, McCready T, et al
Patient-reported symptoms after minimally invasive hysterectomy and association with postoperative complications.
Gynecol Oncol. 2023;175:163-168.
PubMed Abstract available

MORTON M, Patterson J, Sciuva J, Perni J, et al
Malnutrition, sarcopenia, and cancer cachexia in gynecologic cancer.
Gynecol Oncol. 2023;175:142-155.
PubMed Abstract available

LI J, Xue X, Zhang Y, Ding F, et al
The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
Gynecol Oncol. 2023;175:133-141.
PubMed Abstract available

SAINI A, Suh L, Gao J, Leung K, et al
Intra-operative tumor spillage in minimally invasive surgery for endometrial cancer and its impact on recurrence risk.
Gynecol Oncol. 2023;175:128-132.
PubMed Abstract available

SMITH AJB, Puttaraju T, Applebaum J, Fader AN, et al
Long-term impact of the Affordable Care Act's dependent coverage mandate on young women with gynecologic cancer.
Gynecol Oncol. 2023;175:121-127.
PubMed Abstract available

COLOMBO N, Gadducci A, Landoni F, Lorusso D, et al
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol. 2023 Jun 22:S0090-8258(23)00306.
PubMed Abstract available

ANDERSON C, Peery AF, Bae-Jump VL, Brewster WR, et al
Gastrointestinal outcomes among older women with endometrial cancer.
Gynecol Oncol. 2023;175:114-120.
PubMed Abstract available

ZHENG S, Wu Y, Donnelly ED, Strauss JB, et al
A cost-effective, machine learning-based new unified risk-classification score (NU-CATS) for patients with endometrial cancer.
Gynecol Oncol. 2023;175:97-106.
PubMed Abstract available

GWACHAM NI, Kilowski KA, Recio FO, Awada A, et al
Malignant peritoneal cytologic contamination with robotic hysterectomy for endometrial cancer.
Gynecol Oncol. 2023;175:93-96.
PubMed Abstract available

WILEY RL, Urbauer DL, Nugent E, Gallegos J, et al
Endometrial cancer patients understanding and interest in weight loss surgery.
Gynecol Oncol. 2023;175:88-92.
PubMed Abstract available

MORTON M, Haight PJ, Khadraoui W, Backes F, et al
"More than a song and dance": Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok.
Gynecol Oncol. 2023;175:81-87.
PubMed Abstract available

BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al
Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study.
Gynecol Oncol. 2023;175:72-80.
PubMed Abstract available

WINTER MC, Tidy JA, Singh K, Sarwar N, et al
Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
Gynecol Oncol. 2023;175:66-71.
PubMed Abstract available

SILBERMAN JN, Bercow AS, Gockley AA, Eisenhauer EL, et al
Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Gynecol Oncol. 2023;175:60-65.
PubMed Abstract available

KULKARNI A, Chen L, Gockley A, Khoury-Collado F, et al
Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals.
Gynecol Oncol. 2023;175:53-59.
PubMed Abstract available

HAIGHT PJ, Riedinger CJ, Backes FJ, O'Malley DM, et al
The right time for change: A report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria.
Gynecol Oncol. 2023;175:32-40.
PubMed Abstract available

POTHURI B, Blank SV, Myers TK, Hines JF, et al
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
Gynecol Oncol. 2023;174:278-287.
PubMed

SMITH AJB, Alvarez R, Heintz J, Simpkins F, et al
Disparities in clinical trial participation in ovarian cancer: A real-world analysis.
Gynecol Oncol. 2023;175:25-31.
PubMed Abstract available

KARPEL HC, Smith M, Brodsky A, Pothuri B, et al
Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancer.
Gynecol Oncol. 2023;175:20-24.
PubMed Abstract available

NICHOLSON K, Macharia A, Furuya R, Manning C, et al
Association of body mass index with early age at diagnosis of endometrial intraepithelial neoplasia.
Gynecol Oncol. 2023;175:15-19.
PubMed Abstract available

BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Gynecol Oncol. 2023 Jun 2:S0090-8258(23)00299.
PubMed

HOLTZMAN S, Stoffels G, Flint M, Carr C, et al
Outcomes for patients with high-risk endometrial cancer undergoing sentinel lymph node assessment versus full lymphadenectomy.
Gynecol Oncol. 2023;174:273-277.
PubMed Abstract available

LJUNGQVIST O
Gynecologic oncology surgery - Ready for the next step in ERAS.
Gynecol Oncol. 2023;173:A1-A2.
PubMed

LEVINE MD, Barrington DA, Meade CE, Lammers SM, et al
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
Gynecol Oncol. 2023;173:15-21.
PubMed Abstract available

May 2023

SIA TY, Basaran D, Dagher C, Sassine D, et al
Laparoscopy with or without robotic assistance does not negatively impact long-term oncologic outcomes in patients with uterine serous carcinoma.
Gynecol Oncol. 2023;175:8-14.
PubMed Abstract available

PEIPERT JD, Goble S, Isaacson J, Tang X, et al
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Gynecol Oncol. 2023;175:1-7.
PubMed Abstract available

RIOS-DORIA E, Momeni-Boroujeni A, Friedman CF, Selenica P, et al
Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.
Gynecol Oncol. 2023;174:262-272.
PubMed Abstract available

PETERS PN, Havrilesky LJ, Davidson BA
Guidelines for goals of care discussions in patients with gynecologic cancer.
Gynecol Oncol. 2023;174:247-252.
PubMed Abstract available

SCHIFFMAN M, Mirabello L, Egemen D, Befano B, et al
The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.
Gynecol Oncol. 2023;174:253-261.
PubMed Abstract available

EMBABY A, Kutzera J, Geenen JJ, Pluim D, et al
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Gynecol Oncol. 2023;174:239-246.
PubMed Abstract available

KIM J, Kim SI, Kim NR, Kim H, et al
Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Gynecol Oncol. 2023;174:231-238.
PubMed Abstract available

KIM NR, Kim SI, Suh DH, Kim HS, et al
Survival outcomes of laparoscopic versus open radical hysterectomy in early cervical cancer with incidentally identified high-risk factors.
Gynecol Oncol. 2023;174:224-230.
PubMed Abstract available

PRAISS AM, Miller A, Smith J, Lichtman SM, et al
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Gynecol Oncol. 2023;174:213-223.
PubMed Abstract available

DEMARI JA, Dressler EV, Foraker RE, Wells BJ, et al
Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA).
Gynecol Oncol. 2023;174:208-212.
PubMed Abstract available

EURICH K, De La Cruz P, Laguna A, Woodman M, et al
Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer.
Gynecol Oncol. 2023;174:200-207.
PubMed Abstract available

HANVIC B, Lecuru F, Vanacker H, Pautier P, et al
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salome study including 469 patients. A TMRG and GINECO group study.
Gynecol Oncol. 2023;174:190-199.
PubMed Abstract available

KNIPPRATH-MESZAROS AM, Tozzi A, Butenschon A, Reina H, et al
High negative prediction for the Basel sarcoma score: Sonographic assessment of features suspicious of uterine sarcoma.
Gynecol Oncol. 2023;174:182-189.
PubMed Abstract available

QIU Y, Zha J, Ma A, Zhou T, et al
Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol. 2023;174:175-181.
PubMed Abstract available

HAN L, Chen Y, Zheng A, Chen H, et al
Effect of preoperative cervical conization before hysterectomy on survival and recurrence of patients with cervical cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;174:167-174.
PubMed Abstract available

RIMEL BJ, Crane EK, Hou J, Nakayama J, et al
Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations.
Gynecol Oncol. 2023;174:148-156.
PubMed Abstract available

FENG Z, Fu Y, Li R, Li H, et al
Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of epithelial ovarian cancer patients.
Gynecol Oncol. 2023;174:142-147.
PubMed Abstract available

THOMSON JP, Hollis RL, van Baal J, Ilenkovan N, et al
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Gynecol Oncol. 2023;174:157-166.
PubMed Abstract available

XU Z, Yang B, Shan W, Liao J, et al
Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: A prospective, open-label, randomized controlled phase II study.
Gynecol Oncol. 2023;174:133-141.
PubMed Abstract available

KIM SR, Madariaga A, Hogen L, Vicus D, et al
Safety of fertility sparing management in invasive mucinous ovarian carcinoma.
Gynecol Oncol. 2023;174:129-132.
PubMed Abstract available

WITJES VM, Ligtenberg MJL, Vos JR, Braspenning JCC, et al
The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
Gynecol Oncol. 2023;174:121-128.
PubMed Abstract available

MOYETT JM, Howell EP, Broadwater G, Greene M, et al
Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score.
Gynecol Oncol. 2023;174:114-120.
PubMed Abstract available

NEWCOMER MM, Dorayappan KDP, Wagner V, Suarez AA, et al
Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles.
Gynecol Oncol. 2023;173:138-150.
PubMed Abstract available

BEAVIS AL, Blechter B, Najjar O, Fader AN, et al
Identifying women 45 years and younger at elevated risk for endometrial hyperplasia or cancer.
Gynecol Oncol. 2023;174:98-105.
PubMed Abstract available

LEE AJ, Yang EJ, Kim NK, Kim Y, et al
Fertility-sparing hormonal treatment in patients with stage I endometrial cancer of grade 2 without myometrial invasion and grade 1-2 with superficial myometrial invasion: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-2001).
Gynecol Oncol. 2023;174:106-113.
PubMed Abstract available

ALGERA MD, Slangen BFM, van Driel WJ, Wouters MWJM, et al
Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study.
Gynecol Oncol. 2023;174:89-97.
PubMed Abstract available

VERGOTE I, Van Nieuwenhuysen E, Casado A, Laenen A, et al
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
Gynecol Oncol. 2023;174:80-88.
PubMed Abstract available

ROBOVA H, Rob L, Halaska MJ, Drozenova J, et al
Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Pregnancy outcomes.
Gynecol Oncol. 2023;174:76-79.
PubMed Abstract available

FU H, Zhang J, Zhao S, He N, et al
Survival outcomes of robotic-assisted laparoscopy versus conventional laparoscopy and laparotomy for endometrial cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;174:55-67.
PubMed Abstract available

DI DONATO V, Bogani G, Casarin J, Ghezzi F, et al
Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for "low-risk" early-stage cervical cancer: A propensity-score based analysis.
Gynecol Oncol. 2023;174:49-54.
PubMed Abstract available

HUI C, Mendoza MG, Snyder J, Dorigo O, et al
Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control.
Gynecol Oncol. 2023;174:42-48.
PubMed Abstract available

SIA TY, Gordhandas SB, Birsoy O, Kemel Y, et al
Germline drivers of gynecologic carcinosarcomas.
Gynecol Oncol. 2023;174:34-41.
PubMed Abstract available

STOLER MH, Parvu V, Yanson K, Andrews J, et al
Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
Gynecol Oncol. 2023;174:68-75.
PubMed Abstract available

SIA TY, Tew WP, Purdy C, Chi DS, et al
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Gynecol Oncol. 2023;173:130-137.
PubMed Abstract available

CORONADO PJ, Alonso-Espias M, Yildirim Y, Macuks R, et al
Lymph node dissection in uterine leiomyosarcomas: A matched-pair study.
Gynecol Oncol. 2023;174:28-33.
PubMed Abstract available

PIEDIMONTE S, Helpman L, Pond G, Nelson G, et al
Surgical margin status in relation to surgical approach in the management of early-stage cervical Cancer: A Canadian cervical Cancer collaborative (4C) study.
Gynecol Oncol. 2023;174:21-27.
PubMed Abstract available

BAKKUM-GAMEZ JN, Sherman ME, Slettedahl SW, Mahoney DW, et al
Detection of endometrial cancer using tampon-based collection and methylated DNA markers.
Gynecol Oncol. 2023;174:11-20.
PubMed Abstract available

SAMUEL D, Kwon D, Huang M, Zhao W, et al
Disparities in refusal of surgery for gynecologic cancer.
Gynecol Oncol. 2023;174:1-10.
PubMed Abstract available

FUREY KB, Anderson ZS, Kuznicki ML, Klar M, et al
Increasing trends of cervical conization with lymph node evaluation for fertility-sparing surgery in early cervical cancer.
Gynecol Oncol. 2023;173:122-129.
PubMed Abstract available

BEDNAR EM, Chen M, Walsh MT Jr, Eppolito AL, et al
Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems.
Gynecol Oncol. 2023;172:106-114.
PubMed Abstract available

VESTERGAARD AHS, Neergaard MA, Fokdal LU, Christiansen CF, et al
Utilisation of hospital-based specialist palliative care in patients with gynaecological cancer: Temporal trends, predictors and association with high-intensity end-of-life care.
Gynecol Oncol. 2023;172:1-8.
PubMed Abstract available

April 2023

HANDLEY KF, Mehta S, Martin AL, Biswas S, et al
Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma.
Gynecol Oncol. 2023;173:114-121.
PubMed Abstract available

PEREZ L, Webster E, Bull L, Brewer JT, et al
Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.
Gynecol Oncol. 2023;173:106-113.
PubMed Abstract available

GAUDUCHON T, Kfoury M, Lorusso D, Floquet A, et al
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Gynecol Oncol. 2023;173:98-105.
PubMed Abstract available

KIM SI, Nam SH, Hwangbo S, Kim Y, et al
Conization before radical hysterectomy in patients with early-stage cervical cancer: A Korean multicenter study (COBRA-R).
Gynecol Oncol. 2023;173:88-97.
PubMed Abstract available

ORELLANA TJ, Kim H, Beriwal S, Taylor SE, et al
Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer.
Gynecol Oncol. 2023;173:81-87.
PubMed Abstract available

KANG OJ, Nam JH, Park JY
Laparo-endoscopic single-site versus conventional laparoscopic surgery for early-stage endometrial cancer: A randomized controlled non-inferiority trial.
Gynecol Oncol. 2023;173:74-80.
PubMed Abstract available

SCANLON LR, Khaksari B, Goel S, Nevadunsky NS, et al
Direct oral anticoagulant (DOACs) prescribing practices of members of the Society of Gynecologic Oncology and American Society of Clinical Oncology.
Gynecol Oncol. 2023;173:68-73.
PubMed Abstract available

NELSON G, Fotopoulou C, Taylor J, Glaser G, et al
Enhanced recovery after surgery (ERAS(R)) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update.
Gynecol Oncol. 2023;173:58-67.
PubMed Abstract available

GARCIA-SAYRE J, Lin YG, Matuso K, Tsao-Wei DD, et al
Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer.
Gynecol Oncol. 2023;173:49-57.
PubMed Abstract available

CIBULA D
The group with the most heterogenous treatment among patients with cervical cancer.
Gynecol Oncol. 2023 Apr 17:S0090-8258(23)00169.
PubMed

MARCHOCKI Z, Cusimano MC, Vicus D, Pulman K, et al
Diagnostic accuracy of frozen section and patterns of nodal spread in high grade endometrial cancer: A secondary outcome of the SENTOR prospective cohort study.
Gynecol Oncol. 2023;173:41-48.
PubMed Abstract available

CHANG X, Tamauchi S, Yoshida K, Yoshihara M, et al
Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway.
Gynecol Oncol. 2023;173:31-40.
PubMed Abstract available

PIGNATA S, Oza A, Hall G, Pardo B, et al
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Gynecol Oncol. 2023;172:121-129.
PubMed Abstract available

HERNANDEZ-ZEPEDA ML, Munro EG, Caughey AB, Bruegl AS, et al
Ovarian preservation compared to oophorectomy in premenopausal women with early-stage, low-grade endometrial Cancer: A cost-effectiveness analysis.
Gynecol Oncol. 2023;173:8-14.
PubMed Abstract available

SCHWARTZ ZP, Li AJ, Walsh CS, Rimel BJ, et al
Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
Gynecol Oncol. 2023;173:1-7.
PubMed Abstract available

MORELL A, Samborski A, Williams D, Anderson E, et al
Calculating surgical readmission rates in gynecologic oncology: The impact of patient factors.
Gynecol Oncol. 2023;172:115-120.
PubMed Abstract available

March 2023

BRUCE SF, Wu S, Ribeiro JR, Farrell A, et al
HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Gynecol Oncol. 2023;172:98-105.
PubMed Abstract available

BERLIN E, Yegya-Raman N, Garver E, Li T, et al
Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.
Gynecol Oncol. 2023;172:92-97.
PubMed Abstract available

AREND R, Dholakia J, Castro C, Matulonis U, et al
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Gynecol Oncol. 2023;172:82-91.
PubMed Abstract available

SHALOWITZ DI, Schroeder MC, Birken SA
An implementation science approach to the systematic study of access to gynecologic cancer care.
Gynecol Oncol. 2023;172:78-81.
PubMed Abstract available

MUSACCHIO L, Turinetto M, Arenare L, Bartoletti M, et al
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol. 2023;172:72-77.
PubMed Abstract available

MCNAMARA B, Harold J, Manavella D, Bellone S, et al
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
Gynecol Oncol. 2023;172:65-71.
PubMed Abstract available

MOMENI-BOROUJENI A, Vanderbilt C, Yousefi E, Abu-Rustum NR, et al
Landscape of chromatin remodeling gene alterations in endometrial carcinoma.
Gynecol Oncol. 2023;172:54-64.
PubMed Abstract available

HAPUARACHI B, Tidy JA, Romanowski C, Singh K, et al
Leptomeningeal disease as a presenting feature of gestational trophoblastic neoplasia: A review and recommendations for management.
Gynecol Oncol. 2023;172:47-53.
PubMed Abstract available

GRUBBS AE, Sinha N, Garg R, Barber EL, et al
Use of topic modeling to assess research trends in the journal Gynecologic Oncology.
Gynecol Oncol. 2023;172:41-46.
PubMed Abstract available

STRAUBHAR AM, Zhou Q, Iasonos A, Clarke-Pearson DL, et al
Cross-sectional survey of surgical practices among gynecologic oncologists in the United States.
Gynecol Oncol. 2023;172:36-40.
PubMed Abstract available

OLULORO A, Temkin SM, Jackson J, Swisher EM, et al
What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women.
Gynecol Oncol. 2023;172:29-35.
PubMed Abstract available

WEI Z, Luy DD, Tang LW, Deng H, et al
Gamma Knife radiosurgery for gynecologic metastases to the brain: Analysis of pathology, survival, and tumor control.
Gynecol Oncol. 2023;172:21-28.
PubMed Abstract available

OSANN K, Wenzel L, McKinney C, Wagner L, et al
Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
Gynecol Oncol. 2023;171:151-158.
PubMed Abstract available

SPENARD E, Geerts W, Lin Y, Gien LT, et al
Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy.
Gynecol Oncol. 2023;172:9-14.
PubMed Abstract available

LECHARTIER C, Bernard J, Renaud MC, Plante M, et al
Robotic-assisted surgery for endometrial cancer is safe in morbidly and extremely morbidly obese patients.
Gynecol Oncol. 2023;172:15-20.
PubMed Abstract available

TEWARI KS, Sill MW, Birrer MJ, Penson RT, et al
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical Cancer: A NRG oncology randomized study.
Gynecol Oncol. 2023;171:141-150.
PubMed Abstract available

HITCHINS MP, Alvarez R, Zhou L, Aguirre F, et al
MLH1-methylated endometrial cancer under 60 years of age as the "sentinel" cancer in female carriers of high-risk constitutional MLH1 epimutation.
Gynecol Oncol. 2023;171:129-140.
PubMed Abstract available

BJORNHOLT SM, Sponholtz SE, Mogensen O, Bouchelouche K, et al
The SENTIREC-endo study - Risks and benefits of a national adoption of sentinel node mapping in low and intermediate risk endometrial cancer.
Gynecol Oncol. 2023;171:121-128.
PubMed Abstract available

MOOLENAAR LR, van Rangelrooij LE, van Poelgeest MIE, van Beurden M, et al
Clinical outcomes of pelvic exenteration for gynecologic malignancies.
Gynecol Oncol. 2023;171:114-120.
PubMed Abstract available

FOTOPOULOU C
Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a "pelvic" surgeon.
Gynecol Oncol. 2023;170:A1-A3.
PubMed

LEE SS, Karpel HC, Oh C, Smith J, et al
Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
Gynecol Oncol. 2023;170:234-240.
PubMed Abstract available

COLLARINO A, Fuoco V, Garganese G, Pasciuto T, et al
Lymphatic mapping and sentinel node biopsy in vulvar melanoma: the first multicenter study and systematic review.
Gynecol Oncol. 2023;170:153-159.
PubMed Abstract available

STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
Gynecol Oncol. 2023;170:143-152.
PubMed Abstract available

LIU YL, Manning-Geist BL, Knezevic A, Deng L, et al
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Gynecol Oncol. 2023;170:93-101.
PubMed Abstract available

HAROLD J, Bellone S, Manavell DD, Mutlu L, et al
Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
Gynecol Oncol. 2023;170:334.
PubMed

BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Gynecol Oncol. 2023;171:106-113.
PubMed Abstract available

February 2023

GADDUCCI A, Multinu F, De Vitis LA, Cosio S, et al
Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Gynecol Oncol. 2023;171:95-105.
PubMed Abstract available

HENDRIKSE CSE, Theelen PMM, van der Ploeg P, Westgeest HM, et al
The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;171:83-94.
PubMed Abstract available

BLANK SV, Huh WK, Bell M, Dilley S, et al
Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.
Gynecol Oncol. 2023;171:76-82.
PubMed Abstract available

BENBROOK DM, Deng W, Gold MA, Rai R, et al
Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study.
Gynecol Oncol. 2023;171:67-75.
PubMed Abstract available

VAN KOL KGG, Ebisch RMF, van der Aa M, Wenzel HB, et al
The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
Gynecol Oncol. 2023;171:9-14.
PubMed Abstract available

TANG H, Fayomi AP, Bai S, Gupta N, et al
Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy.
Gynecol Oncol. 2023;171:49-58.
PubMed Abstract available

LI G, Xu W, Li X, Chen M, et al
Oncogenic SIRT7 inhibits GATA4 transcriptional activity and activates the Wnt signaling pathway in ovarian cancer.
Gynecol Oncol. 2023;171:39-48.
PubMed Abstract available

ALIMENA S, Fallah P, Stephenson B, Feltmate C, et al
Comparison of Enhanced Recovery After Surgery (ERAS) metrics by race among gynecologic oncology patients: Ensuring equitable outcomes.
Gynecol Oncol. 2023;171:31-38.
PubMed Abstract available

PRAISS AM, Zhou Q, Iasonos A, Moukarzel L, et al
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
Gynecol Oncol. 2023;171:23-30.
PubMed Abstract available

DESSOURCES K, Ferrando L, Zhou QC, Iasonos A, et al
Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype.
Gynecol Oncol. 2023;171:15-22.
PubMed Abstract available

JIANG S, Zhao J, Shi X, Wu H, et al
Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor.
Gynecol Oncol. 2023;171:1-8.
PubMed Abstract available

JORGENSEN K, Melamed A, Wu CF, Nitecki R, et al
Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
Gynecol Oncol. 2023 Feb 10:S0090-8258(23)00017.
PubMed Abstract available

O'MALLEY DM, Ledermann JA, Coleman RL
Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".
Gynecol Oncol. 2023 Feb 9:S0090-8258(23)00049.
PubMed

KIM C, Salvo G, Ishikawa M, Chen TC, et al
The role of postoperative radiation after radical hysterectomy for women with early-stage neuroendocrine carcinoma of the cervix: A meta-analysis.
Gynecol Oncol. 2023;170:328-332.
PubMed Abstract available

LIANG MI, Harrison R, Aviki EM, Esselen KM, et al
Financial toxicity: A practical review for gynecologic oncology teams to understand and address patient-level financial burdens.
Gynecol Oncol. 2023;170:317-327.
PubMed Abstract available

KISSEL M, Balaya V, Guani B, Magaud L, et al
Impact of preoperative brachytherapy followed by radical hysterectomy in stage IB2 (FIGO 2018) cervical cancer: An analysis of SENTICOL I-II trials.
Gynecol Oncol. 2023;170:309-316.
PubMed Abstract available

HERZOG TJ, Pignata S, Ghamande SA, Rubio MJ, et al
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol. 2023;170:300-308.
PubMed Abstract available

WIESER V, Tsibulak I, Reimer DU, Zeimet AG, et al
An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Gynecol Oncol. 2023;170:290-299.
PubMed Abstract available

JAMIESON A, Huvila J, Leung S, Chiu D, et al
Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer.
Gynecol Oncol. 2023;170:282-289.
PubMed Abstract available

JANSEN A, de Jong A, Hoogendam JP, Baeten IGT, et al
Lymphocele following lymph node dissection in cervical and endometrial cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;170:273-281.
PubMed Abstract available

KAUR A, Wang S, Kumar A
Impact of racial disparities on potential years of life lost due to gynecologic cancer in the United States: Trends from 1975 to 2017 based on SEER database.
Gynecol Oncol. 2023;170:266-272.
PubMed Abstract available

KOFOED NG, Falconer H, Vanky H, Johansson H, et al
Survival and chance of reversal after intestinal stoma formation during cytoreductive surgery for advanced ovarian cancer; a population-based cohort study.
Gynecol Oncol. 2023;170:259-265.
PubMed Abstract available

KOEHLER L, Penz LE, John F, Stenzel A, et al
Functional and psychosocial quality of life in gynecologic Cancer survivors with and without lymphedema symptoms.
Gynecol Oncol. 2023;170:254-258.
PubMed Abstract available

HOLLOWAY SB, Mercadel AJ, Miller DS, Lea JS, et al
Isolated para-aortic nodal recurrence after treatment of early stage cervical carcinoma.
Gynecol Oncol. 2023;170:248-253.
PubMed Abstract available

GILBERT L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, et al
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gynecol Oncol. 2023;170:241-247.
PubMed Abstract available

BOITANO TKL, Scarinci IC
Targeting our efforts: the contribution of an open-access tool to assess geographic distribution of recurrent and metastatic cervical cancer.
Gynecol Oncol. 2023;169:A1-A2.
PubMed

BERCOW AS, Rauh-Hain JA, Melamed A, Mazina V, et al
Association of hospital-level factors with utilization of sentinel lymph node biopsy in patients with early-stage vulvar cancer.
Gynecol Oncol. 2023;169:47-54.
PubMed Abstract available

BRASKY TM, Hade EM, Cohn DE, Newton AM, et al
Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis.
Gynecol Oncol. 2023;169:137-146.
PubMed Abstract available

January 2023

STRAUBHAR AM, Stroup C, de Bear O, Dalton L, et al
Provider compliance with a tailored opioid prescribing calculator in gynecologic surgery.
Gynecol Oncol. 2023;170:229-233.
PubMed Abstract available

DAVIDSON TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, et al
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol. 2023;170:221-228.
PubMed Abstract available

ZHANG Y, Yang R, Xu C, Zhang Y, et al
Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study.
Gynecol Oncol. 2023;170:210-220.
PubMed Abstract available

HAIGHT PJ, Barrington DA, Graves SM, Piver RN, et al
Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient population.
Gynecol Oncol. 2023;170:203-209.
PubMed Abstract available

JAMIESON A, Singh N, Huvila J, Gilks CB, et al
The continuing evolution of endometrial carcinoma molecular classification: Risk stratification within the No Specific Molecular Profile (NSMP) subtype.
Gynecol Oncol. 2023 Jan 26:S0090-8258(22)02019.
PubMed

CIBULA D, Akilli H, Jarkovsky J, van Lonkhuijzen L, et al
Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.
Gynecol Oncol. 2023;170:195-202.
PubMed Abstract available

FERRON G, De Rauglaudre G, Becourt S, Delanoy N, et al
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecol Oncol. 2023;170:186-194.
PubMed Abstract available

BRAGA A, Andrade T, do Carmo Borges de Souza M, Campos V, et al
Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception - a retrospective cohort study and lit
Gynecol Oncol. 2023;170:179-185.
PubMed Abstract available

HAN C, McNamara B, Bellone S, Harold J, et al
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol. 2023;170:172-178.
PubMed Abstract available

MOUFARRIJ S, Sassine D, Basaran D, Jewell EL, et al
Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
Gynecol Oncol. 2023;170:167-171.
PubMed Abstract available

MITRIC C, Salman L, Abrahamyan L, Kim SR, et al
Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;170:133-142.
PubMed Abstract available

SUVAAL I, Kirchheiner K, Nout RA, Sturdza AE, et al
Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy.
Gynecol Oncol. 2023;170:123-132.
PubMed Abstract available

JAREEMIT N, Therasakvichya S, Freitas F, Paiva G, et al
EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.
Gynecol Oncol. 2023;170:114-122.
PubMed Abstract available

NAVARRO AS, Gomez CM, Angeles MA, Fuzier R, et al
Open abdominal vacuum pack technique for the management of severe abdominal complications after cytoreductive surgery in ovarian cancer.
Gynecol Oncol. 2023;170:108-113.
PubMed Abstract available

JOHNSON AM, Teoh D, Jewett P, Darst BF, et al
Genetic variants associated with post-traumatic stress symptoms in patients with gynecologic cancer.
Gynecol Oncol. 2023;170:102-107.
PubMed Abstract available

SMITS A, Ten Eikelder M, Dhanis J, Moore W, et al
Finding the sentinel lymph node in early cervical cancer: When is unusual not uncommon?
Gynecol Oncol. 2023;170:84-92.
PubMed Abstract available

ORELLANA TJ, Garrett AA, Soong TR, Rives T, et al
The role of adjuvant treatment for early-stage uterine clear cell carcinomas.
Gynecol Oncol. 2023;170:77-83.
PubMed Abstract available

SHIRLEY J, Lambert P, Nachtigal MW, Altman AD, et al
A comparison of synoptic reports and dictated reports to enhance and standardize surgical documentation and quality of care in epithelial ovarian cancer.
Gynecol Oncol. 2023;170:54-58.
PubMed Abstract available

TOGAMI S, Tanimoto A, Yanazume S, Tokunaga H, et al
Evaluation of the one-step nucleic acid amplification assay for detecting lymph node metastasis in patients with cervical and endometrial cancer: A multicenter prospective study.
Gynecol Oncol. 2023;170:70-76.
PubMed Abstract available

LU L, Liu T, Wang S, Li J, et al
Joint detection of multiple HPV-testing technologies and evaluation of clinicopathological characteristics discriminate between HPV-independent and low-copy HPV-associated cervical squamous cell carcinoma (CSCC) -an analysis of 3869 cases.
Gynecol Oncol. 2023;170:59-69.
PubMed Abstract available

KAHN RM, McMinn E, Yeoshoua E, Boerner T, et al
Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.
Gynecol Oncol. 2023;170:46-53.
PubMed Abstract available

MAURICIO D, Bellone S, Mutlu L, McNamara B, et al
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol. 2023;170:38-45.
PubMed Abstract available

WANG DF, Shi XW, Zhang C, Zhang J, et al
Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
Gynecol Oncol. 2023;170:25-31.
PubMed Abstract available

KIM JH, Chun SY, Lee DE, Woo YH, et al
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).
Gynecol Oncol. 2023;170:19-24.
PubMed Abstract available

THOMSON CA, Crane TE, Miller A, Gold MA, et al
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
Gynecol Oncol. 2023;170:11-18.
PubMed Abstract available

PETERS PN, Rossi EC
Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment?
Gynecol Oncol. 2023;168:A2-A3.
PubMed

December 2022

ASIF H, Foley G, Simon M, Roque D, et al
Analysis of endometrial carcinoma TCGA reveals differences in DNA methylation in tumors from Black and White women.
Gynecol Oncol. 2022;170:1-10.
PubMed Abstract available

DINIZ TP, Menezes JN, Goncalves BT, Faloppa CC, et al
Can mismatch repair status be added to sentinel lymph node mapping algorithm in endometrioid endometrial cancer?
Gynecol Oncol. 2022;169:131-136.
PubMed Abstract available

EHMANN S, Shay K, Zhou Q, Iasonos A, et al
Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2022;169:118-124.
PubMed Abstract available

CASTELLANO T, Moore K, Ting J, Washington C, et al
Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.
Gynecol Oncol. 2022;169:113-117.
PubMed Abstract available

LI X, Jiang Z, Lu J, Chen X, et al
Neoadjuvant chemotherapy followed by radical trachelectomy versus upfront abdominal radical trachelectomy for patients with FIGO 2018 stage IB2 cervical cancer.
Gynecol Oncol. 2022;169:106-112.
PubMed Abstract available

ARMSTRONG DK
AML and MDS associated with PARP inhibitor treatment of ovarian cancer.
Gynecol Oncol. 2022 Dec 15:S0090-8258(22)01961.
PubMed

MANAVELLA DD, McNamara B, Harold J, Bellone S, et al
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Gynecol Oncol. 2022;169:98-105.
PubMed Abstract available

LIN MY, Mileshkin L, McNally O, Kondalsamy-Chennakesavan S, et al
Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection.
Gynecol Oncol. 2022;169:91-97.
PubMed Abstract available

KAHN R, Filippova O, Gordhandas S, An A, et al
Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors.
Gynecol Oncol. 2022;169:85-90.
PubMed Abstract available

COLOMBA E, Alexandre J, Le Teuff G, Genestie C, et al
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
Gynecol Oncol. 2022;169:78-84.
PubMed Abstract available

BOONE RM, Praiss AM, Huang Y, Melamed A, et al
Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials.
Gynecol Oncol. 2022;169:70-77.
PubMed Abstract available

RUBINSTEIN MM, Doria ER, Konner J, Lichtman S, et al
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Gynecol Oncol. 2022;169:64-69.
PubMed Abstract available

WOOD N, Morton M, Shah SN, Yao M, et al
Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer.
Gynecol Oncol. 2022;169:55-63.
PubMed Abstract available

REID HW, Selvan B, Montes de Oca MK, Falkovic M, et al
"You start feeling comfortable, you just start sharing:" A qualitative study of patient distress screening in Black and White patients with endometrial cancer.
Gynecol Oncol. 2022;168:166-175.
PubMed Abstract available

NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma.
Gynecol Oncol. 2022;169:41-46.
PubMed Abstract available

PARKER VL, Cushen BF, Hills A, Kandiah K, et al
Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
Gynecol Oncol. 2022;169:34-40.
PubMed Abstract available

DI DIO C, Bogani G, Di Donato V, Cuccu I, et al
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Gynecol Oncol. 2022;169:27-33.
PubMed Abstract available

DU J, Cheng Y, Hu D, Xing Y, et al
A nomogram-based overall survival stratification to identify uterine sarcoma patients without distant metastases who may benefit from adjuvant radiotherapy.
Gynecol Oncol. 2022;169:17-26.
PubMed Abstract available

KIM SR, Ene GEV, Simpson A, Gesink D, et al
Acceptability of bariatric surgery in people with endometrial cancer and atypical hyperplasia: A qualitative study.
Gynecol Oncol. 2022;169:12-16.
PubMed Abstract available

MATULONIS UA
The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data.
Gynecol Oncol. 2022;167:401-403.
PubMed

EHMANN S, Sassine D, Straubhar AM, Praiss AM, et al
Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.
Gynecol Oncol. 2022;167:458-466.
PubMed Abstract available

November 2022

VIEIRA-SERNA S, Viveros-Carreno D, Rodriguez J, Grillo-Ardila CF, et al
Preoperative brachytherapy for early-stage cervical cancer: Systematic review and meta-analysis.
Gynecol Oncol. 2022;169:4-11.
PubMed Abstract available

CRUM CP, Yoon JY, Feltmate CM
Clinical commentary extra-uterine high-grade serous carcinoma: Two pathways, two preventions?
Gynecol Oncol. 2022;169:1-3.
PubMed

ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
Gynecol Oncol. 2022 Nov 28:S0090-8258(22)01924.
PubMed

HAROLD J, Bellone S, Manavella DD, Mutlu L, et al
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Gynecol Oncol. 2022;168:157-165.
PubMed Abstract available

DOSTALEK L, Benesova K, Klat J, Kim SH, et al
Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project.
Gynecol Oncol. 2022;168:151-156.
PubMed Abstract available

SALINARO JR, Zanolli N, Truong T, Havrilesky LJ, et al
Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative.
Gynecol Oncol. 2022;168:144-150.
PubMed Abstract available

SHU T, Zhou Z, Bai J, Xiao X, et al
Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
Gynecol Oncol. 2022;168:135-143.
PubMed Abstract available

AKESSON A, Adok C, Dahm-Kahler P
Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study.
Gynecol Oncol. 2022;168:127-134.
PubMed Abstract available

KARIA PS, Huang Y, Tehranifar P, Wright JD, et al
Racial and ethnic differences in type II endometrial cancer mortality outcomes: The contribution of sociodemographic, clinicopathologic, and treatment factors.
Gynecol Oncol. 2022;168:119-126.
PubMed Abstract available

MYSONA D, Dorr K, Ward A, Shaver E, et al
Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy.
Gynecol Oncol. 2022;168:114-118.
PubMed Abstract available

WESTIN SN, Fu S, Tsimberidou A, Piha-Paul S, et al
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Gynecol Oncol. 2022;168:76-82.
PubMed Abstract available

MATANES E, Amajoud Z, Kogan L, Mitric C, et al
Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?
Gynecol Oncol. 2022;168:107-113.
PubMed Abstract available

MOUKARZEL LA, Nguyen N, Zhou Q, Iasonos A, et al
Association of bowel preparation with surgical-site infection in gynecologic oncology surgery: Post-hoc analysis of a randomized controlled trial.
Gynecol Oncol. 2022;168:100-106.
PubMed Abstract available

ZHAO L, Qin Y, Ma D, Liu H, et al
Corrigendum to "Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia: A retrospective study" [Gynecologic Oncology Volume 167, Issue 3, Oct 2022 Pages 37-41].
Gynecol Oncol. 2022 Nov 18:S0090-8258(22)01925.
PubMed

MARK J, Fisher DT, Kim M, Emmons T, et al
Carboplatin enhances lymphocyte-endothelial interactions to promote CD8(+) T cell trafficking into the ovarian tumor microenvironment.
Gynecol Oncol. 2022;168:92-99.
PubMed Abstract available

YANAIHARA N, Yoshino Y, Noguchi D, Tabata J, et al
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
Gynecol Oncol. 2022;168:83-91.
PubMed Abstract available

PHUNG MT, Webb PM, DeFazio A, Fereday S, et al
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
Gynecol Oncol. 2022;168:68-75.
PubMed Abstract available

YOU B, Bolze PA, Lotz JP, Massardier J, et al
Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.
Gynecol Oncol. 2022;168:62-67.
PubMed Abstract available

BRUEGL AS, Emerson J, Tirumala K
Persistent disparities of cervical cancer among American Indians/Alaska natives: Are we maximizing prevention tools?
Gynecol Oncol. 2022;168:56-61.
PubMed Abstract available

WALSH CS, Hacker KE, Secord AA, DeLair DF, et al
Molecular testing for endometrial cancer: An SGO clinical practice statement.
Gynecol Oncol. 2022;168:48-55.
PubMed Abstract available

KNAUSS T, Hansen BT, Pedersen K, Aasbo G, et al
The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial.
Gynecol Oncol. 2022;168:39-47.
PubMed Abstract available

KA K, Laville A, Rassy E, Ayachi RE, et al
Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: Clinical outcome and prognostic factors.
Gynecol Oncol. 2022;168:32-38.
PubMed Abstract available

MEAGHER NS, Hamilton P, Milne K, Thornton S, et al
Profiling the immune landscape in mucinous ovarian carcinoma.
Gynecol Oncol. 2022;168:23-31.
PubMed Abstract available

PIAO H, Wu M, Qin S, Tang Z, et al
Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis.
Gynecol Oncol. 2022;168:17-22.
PubMed Abstract available

KIM H, Kim HJ, Ahn HS
Does endometriosis increase the risks of endometrial hyperplasia and endometrial cancer?
Gynecol Oncol. 2022 Nov 7. pii: S0090-8258(22)00425.
PubMed Abstract available

KELKAR SS, Prabhu VS, Corman S, Odak S, et al
Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
Gynecol Oncol. 2022 Nov 4. pii: S0090-8258(22)01893.
PubMed Abstract available

PETERS PN, Moyett JM, Davidson BA, Cantrell S, et al
Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction.
Gynecol Oncol. 2022 Nov 4. pii: S0090-8258(22)01890.
PubMed Abstract available

MUELLER JJ, Rios-Doria E, Park KJ, Broach VA, et al
Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?
Gynecol Oncol. 2022;168:1-7.
PubMed Abstract available

ACKROYD SA, Arguello D, Ramos P, Mahdi H, et al
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
Gynecol Oncol. 2022 Nov 1. pii: S0090-8258(22)01897.
PubMed Abstract available

October 2022

RUBINSTEIN M, Shen S, Monk BJ, Tan DSP, et al
Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
Gynecol Oncol. 2022 Oct 21. pii: S0090-8258(22)01889.
PubMed Abstract available

O'MALLEY DM, Oza AM, Lorusso D, Aghajanian C, et al
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)00575.
PubMed Abstract available

KIM SI, Kim JH, Lee S, Cho H, et al
Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)01887.
PubMed Abstract available

JORGE S
Health Equity in Gynecologic Oncology: Focus on Limited English Proficiency.
Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)01861.
PubMed

CHENG A, Rao Q, Liu Y, Huang C, et al
Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
Gynecol Oncol. 2022 Oct 18. pii: S0090-8258(22)01888.
PubMed Abstract available

HINCHCLIFF E, Rumpf J, Ratan R, Fleming ND, et al
Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma.
Gynecol Oncol. 2022 Oct 18. pii: S0090-8258(22)01852.
PubMed Abstract available

EBATA T, Yamashita S, Takeshima H, Yoshida H, et al
DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
Gynecol Oncol. 2022 Oct 14. pii: S0090-8258(22)01881.
PubMed Abstract available

FARLEY JH, Brady WE, O'Malley D, Fujiwara K, et al
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01862.
PubMed Abstract available

CHAN JK, Tian C, Kesterson JP, Richardson MT, et al
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01856.
PubMed Abstract available

SMITH AJB, Mulugeta-Gordon L, Pena D, Kanter GP, et al
Prior authorization in gynecologic oncology: An analysis of clinical impact.
Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01858.
PubMed Abstract available

GARZON S, Grassi T, Mariani A, Kollikonda S, et al
Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01860.
PubMed Abstract available

KURNIT KC, Nobre SP, Fellman BM, Iglesias DA, et al
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
Gynecol Oncol. 2022 Oct 12. pii: S0090-8258(22)01853.
PubMed Abstract available

ELNAGGAR A, Robins D, Baca Y, Arguello D, et al
Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
Gynecol Oncol. 2022 Oct 10. pii: S0090-8258(22)01850.
PubMed Abstract available

MITRA D, Farr M, Nagarajan P, Ho J, et al
Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.
Gynecol Oncol. 2022 Oct 10. pii: S0090-8258(22)01854.
PubMed Abstract available

LORUSSO D, Pignata S, Tamberi S, Mangili G, et al
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01851.
PubMed Abstract available

POWELL CB, Laurent C, Garcia C, Hoodfar E, et al
Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01857.
PubMed Abstract available

VON KARTASCHEW AE, Dahm-Kahler P, Rodriguez-Wallberg KA, Holmberg E, et al
Hormone replacement in premenopausal women treated with bilateral oophorectomy for ovarian cancer - a nationwide population-based study.
Gynecol Oncol. 2022 Oct 7. pii: S0090-8258(22)01855.
PubMed Abstract available

CAO Y, Viswanathan A
When is it safe to omit contralateral groin management in unilateral sentinel node-positive early stage vulvar cancer?
Gynecol Oncol. 2022;167:1-2.
PubMed

VAN DER KOLK WL, Van der Zee AGJ, Slomovitz BM, Baldwin PJW, et al
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.
Gynecol Oncol. 2022;167:3-10.
PubMed Abstract available

PERKINS R, Jeronimo J, Hammer A, Novetsky A, et al
Comparison of accuracy and reproducibility of colposcopic impression based on a single image versus a two-minute time series of colposcopic images.
Gynecol Oncol. 2022;167:89-95.
PubMed Abstract available

CHEN H, Xiong W, Dong X, Liu Y, et al
Infection status and survival impact of high-risk human papillomavirus in cervical adenocarcinomas: A systematic review and meta-analysis.
Gynecol Oncol. 2022;167:129-136.
PubMed Abstract available

September 2022

HELPMAN L, Pond GR, Elit L, Anderson LN, et al
Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study.
Gynecol Oncol. 2022 Sep 30. pii: S0090-8258(22)01829.
PubMed Abstract available

KONSTANTINOPOULOS PA, Lee JM, Gao B, Miller R, et al
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
Gynecol Oncol. 2022 Sep 30. pii: S0090-8258(22)01839.
PubMed Abstract available

HOLM J, Gerke O, Vilstrup MH, Spasojevic D, et al
Improved stratification of stage-specific survival for cervical uterine cancer by integrating FDG-PET/CT and MRI for lymph node staging in 2018 FIGO classification.
Gynecol Oncol. 2022 Sep 28. pii: S0090-8258(22)01841.
PubMed Abstract available

BUCKLEY E, Mullen MM, Nizamuddin RA, Stein JH, et al
High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer.
Gynecol Oncol. 2022 Sep 27. pii: S0090-8258(22)01824.
PubMed Abstract available

MAH SJ, Seow H, Schnarr K, Reade CJ, et al
Trends in quality indicators of end-of-life care for women with gynecologic malignancies in Ontario, Canada.
Gynecol Oncol. 2022 Sep 23. pii: S0090-8258(22)01822.
PubMed Abstract available

EGAN D, Moran B, Wilkinson M, Pinyol M, et al
CRABP2 - A novel biomarker for high-risk endometrial cancer.
Gynecol Oncol. 2022 Sep 23. pii: S0090-8258(22)01840.
PubMed Abstract available

RIEDINGER CJ, Patterson JM, Backes FJ, O'Malley D, et al
The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)01828.
PubMed Abstract available

YFAT K, Mariam K, Mario B, Hal H, et al
Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)00574.
PubMed Abstract available

GLASER GE, Lara OD, Pothuri B, Grimaldi CG, et al
Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.
Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)01837.
PubMed Abstract available

WICKLINE M, Wolpin S, Cho S, Tomashek H, et al
Usability and acceptability of the electronic self-assessment and care (eSAC) program in advanced ovarian cancer: A mixed methods study.
Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01825.
PubMed Abstract available

BERGER AA, Kawaler EA, Dao F, Misirlioglu S, et al
The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01827.
PubMed Abstract available

RONSINI C, Kohler C, de Franciscis P, La Verde M, et al
Laparo-assisted vaginal radical hysterectomy as a safe option for minimal invasive surgery in early stage cervical cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)00580.
PubMed Abstract available

LEE YW, Morgan JR, Fiascone S, Perkins RB, et al
Underscreenng, overscreening, and guideline-adherent cervical cancer screening in a national cohort.
Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01826.
PubMed Abstract available

GERSHENSON DM, Cobb LP, Westin SN, Zhang Y, et al
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gynecol Oncol. 2022 Sep 19. pii: S0090-8258(22)00591.
PubMed Abstract available

HOU JY, Chapman JS, Kalashnikova E, Pierson W, et al
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
Gynecol Oncol. 2022 Sep 15. pii: S0090-8258(22)00590.
PubMed Abstract available

CROCE S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, et al
Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00515.
PubMed Abstract available

YU S, Yang R, Xu T, Li X, et al
Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00589.
PubMed Abstract available

RUSH SK, Lees BF, Huang DS, Peterson MF, et al
Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes.
Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00577.
PubMed Abstract available

KLC TR, Wu S, Wilhite AM, Jones NL, et al
HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00592.
PubMed Abstract available

VREDE SW, Hulsman AMC, Reijnen C, Van de Vijver K, et al
The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification.
Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00570.
PubMed Abstract available

LI N, Zhu X, Nian W, Li Y, et al
Blood-based DNA methylation profiling for the detection of ovarian cancer.
Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00480.
PubMed Abstract available

PUJADE-LAURAINE E, Tan DSP, Leary A, Mirza MR, et al
Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review.
Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00552.
PubMed Abstract available

VAN STEIN RM, Engbersen MP, Stolk T, Lopez-Yurda M, et al
Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
Gynecol Oncol. 2022 Sep 7. pii: S0090-8258(22)00576.
PubMed Abstract available

MENZIES AV, Usher EC, Hsu FC, Levine EA, et al
HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
Gynecol Oncol. 2022 Sep 6. pii: S0090-8258(22)00569.
PubMed Abstract available

DAVIDSON BA, Turner TB, Kim KH, Cass I, et al
SGO and the elephant that is still in the room: Wellness, burnout and gynecologic oncology.
Gynecol Oncol. 2022 Sep 2. pii: S0090-8258(22)00572.
PubMed Abstract available

LAGO V, Segarra-Vidal B, Cappucio S, Angeles MA, et al
OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery.
Gynecol Oncol. 2022 Sep 1. pii: S0090-8258(22)00542.
PubMed Abstract available

VAN DEN HEERIK ASVM, Aiyer KTS, Stelloo E, Jurgenliemk-Schulz IM, et al
Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
Gynecol Oncol. 2022;166:530-537.
PubMed Abstract available

MATTSON J, Emerson J, Underwood A, Sun G, et al
Superficial versus deep inguinal nodal dissection for vulvar cancer staging.
Gynecol Oncol. 2022;166:465-470.
PubMed Abstract available

KUMAR A
Answering the call: Are we ready for action on frailty in gynecologic oncology?
Gynecol Oncol. 2022;166:377-378.
PubMed

August 2022

POZZAR RA, Xiong N, Hong F, Wright AA, et al
How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods study.
Gynecol Oncol. 2022 Aug 31. pii: S0090-8258(22)00573.
PubMed Abstract available

BUI A, Gehrig PA, Ghamande S, Rungruang BJ, et al
Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting.
Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00551.
PubMed Abstract available

MADARIAGA A, Mitchell SA, Pittman T, Wang L, et al
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovaria
Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00544.
PubMed Abstract available

BOKKERS K, Frederix GWJ, Velthuizen ME, van der Aa M, et al
Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
Gynecol Oncol. 2022 Aug 25. pii: S0090-8258(22)00550.
PubMed Abstract available

ANDERSON C, Olshan AF, Bae-Jump VL, Brewster WR, et al
Cardiovascular disease diagnoses among older women with endometrial cancer.
Gynecol Oncol. 2022 Aug 22. pii: S0090-8258(22)00553.
PubMed Abstract available

LAI YL, Chang CS, Chang K, Kim HS, et al
Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwan.
Gynecol Oncol. 2022 Aug 19. pii: S0090-8258(22)00547.
PubMed Abstract available

THOMAS QD, Boussere A, Classe JM, Pomel C, et al
Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00543.
PubMed Abstract available

KIM Y, Kim SI, Kim H, Lee M, et al
Open versus minimally invasive radical hysterectomy for early cervical cancer: A two-center retrospective cohort study with pathologic review of usual-type adenocarcinoma and adenosquamous carcinoma.
Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00541.
PubMed Abstract available

VAHTERISTO M, Heinavaara S, Anttila A, Sarkeala T, et al
Alternative cytology triage strategies for primary HPV screening.
Gynecol Oncol. 2022 Aug 10. pii: S0090-8258(22)00495.
PubMed Abstract available

DEMARI JA, Shalowitz DI
Routine informed consent for mismatch repair testing in endometrial cancers: Review and ethical analysis.
Gynecol Oncol. 2022 Aug 8. pii: S0090-8258(22)00540.
PubMed Abstract available

MOSS KM, Mishra GD, Krejany EO, Hickey M, et al
What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2022 Aug 3. pii: S0090-8258(22)00513.
PubMed Abstract available

ZHAO L, Qin Y, Ma D, Liu H, et al
Surgical treatment of lung metastasis in patients with refractory gestational trophoblastic neoplasia: A retrospective study.
Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00514.
PubMed Abstract available

KUMAR A, Wang C, Sheedy SP, McCauley BM, et al
Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00492.
PubMed Abstract available

SHAPIRA-FROMMER R, Mileshkin L, Manzyuk L, Penel N, et al
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
Gynecol Oncol. 2022;166:211-218.
PubMed Abstract available

SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
Corrigendum to "Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer" [Gynecologic Oncology, Volume 165, Issue 2, May 2022, Pages 270-280].
Gynecol Oncol. 2022;166:370-371.
PubMed

MARION S, Aviki E, Chino F
Financial toxicity of surgical treatment for gynecological cancer: A growing malignancy.
Gynecol Oncol. 2022;166:197-199.
PubMed

July 2022

SIVARS L, Hellman K, Crona Guterstam Y, Holzhauser S, et al
Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer.
Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00512.
PubMed Abstract available

HOARE JI, Hockings H, Saxena J, Silva VL, et al
A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00511.
PubMed Abstract available

ALHOLM Z, He D, Ting J, Zhang YJ, et al
Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis.
Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00509.
PubMed Abstract available

SHRESTHA P, Poudyal B, Yadollahi S, E Wright D, et al
A systematic review on the use of artificial intelligence in gynecologic imaging - Background, state of the art, and future directions.
Gynecol Oncol. 2022 Jul 29. pii: S0090-8258(22)00496.
PubMed Abstract available

BOGANI G, Donato VD, Scambia G, Landoni F, et al
Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer.
Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00494.
PubMed Abstract available

LEWIS GK, Ghaith S, Craver EC, Li Z, et al
The association of endosalpingiosis with gynecologic malignancy.
Gynecol Oncol. 2022 Jul 28. pii: S0090-8258(22)00510.
PubMed Abstract available

BARRINGTON DA, Calo C, Baek J, Brown M, et al
Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy.
Gynecol Oncol. 2022 Jul 27. pii: S0090-8258(22)00482.
PubMed Abstract available

KIM YN, Lee D, Cha J, Kang WJ, et al
Usefulness and potential pitfalls of pre-operative PET-CT in patients with endometrial cancer undergoing one- and two-step sentinel lymph node mapping: Do negative findings on PET-CT negativity really indicate node negativity?
Gynecol Oncol. 2022 Jul 27. pii: S0090-8258(22)00487.
PubMed Abstract available

JOLY F, Fabbro M, Berton D, Lequesne J, et al
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00426.
PubMed Abstract available

LIANG MI, Simons JL, Herbey I, Wall JA, et al
Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00493.
PubMed Abstract available

The implications of the loss of abortion services from the perspective of the gynecologic cancer care team.
Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00491.
PubMed

BARRINGTON DA, Meade CE, Cosgrove CM, Cohn DE, et al
Racial and ethnic disparities in readmission risk following the surgical management of endometrial cancer.
Gynecol Oncol. 2022 Jul 23. pii: S0090-8258(22)00486.
PubMed Abstract available

SHALOWITZ DI, Charlton ME
The road to geographic equity in access to gynecologic cancer care.
Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00490.
PubMed

LEITAO MM JR, Zhou QC, Brandt B, Iasonos A, et al
The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes.
Gynecol Oncol. 2022 Jul 22. pii: S0090-8258(22)00434.
PubMed Abstract available

LEVINE MD, Barrington DA, Hampel H, Goodfellow PJ, et al
Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations.
Gynecol Oncol. 2022 Jul 20. pii: S0090-8258(22)00488.
PubMed Abstract available

LI H, Wang S, Liu Y, Wang T, et al
Prophylactic extended-field irradiation for locally advanced cervical cancer.
Gynecol Oncol. 2022 Jul 19. pii: S0090-8258(22)00481.
PubMed Abstract available

TUCKER K, Sullivan S, Deal AM, Allman K, et al
A prospective randomized trial of standard versus multimedia-supplemented counseling in patients undergoing endometrial cancer staging surgery.
Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00485.
PubMed Abstract available

ALHILLI MM, Schold JD, Kelley J, Tang AS, et al
Preoperative assessment using the five-factor modified frailty index: A call for standardized preoperative assessment and prehabilitation services in gynecologic oncology.
Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00435.
PubMed Abstract available

KIM SI, Kim JH, Noh JJ, Kim SH, et al
Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00483.
PubMed Abstract available

CHASE DM, Marin MR, Backes F, Han S, et al
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
Gynecol Oncol. 2022 Jul 15. pii: S0090-8258(22)00432.
PubMed Abstract available

BENICHOU J, Schwall C, Sastre-Garau X, Mereaux J, et al
Impact of the new molecular classification of endometrial cancer: A French cohort study.
Gynecol Oncol. 2022 Jul 14. pii: S0090-8258(22)00484.
PubMed Abstract available

HARE CJ, Crangle C, McGarragle K, Ferguson SE, et al
Change in cancer-related fatigue over time predict health-related quality of life in ovarian cancer patients.
Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00433.
PubMed Abstract available

PITIYARACHCHI O, Friedlander M, Java JJ, Chan JK, et al
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (>/=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemothera
Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00436.
PubMed Abstract available

O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00405.
PubMed Abstract available

PIEDIMONTE S, Bernardini MQ, Ding A, Laframboise S, et al
Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
Gynecol Oncol. 2022 Jul 9. pii: S0090-8258(22)00430.
PubMed Abstract available

MCDONALD V, Wang Y, Patel A, Betcher R, et al
Laparoscopic guided liposomal bupivacaine injection compared to transversus abdominus plane block for postoperative pain after robotic gynecologic oncology surgery.
Gynecol Oncol. 2022 Jul 8. pii: S0090-8258(22)00406.
PubMed Abstract available

CADOO K, Simpkins F, Mathews C, Liu YL, et al
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Gynecol Oncol. 2022 Jul 5. pii: S0090-8258(22)00421.
PubMed Abstract available

TSENG JH, Bristow RE
Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles.
Gynecol Oncol. 2022;166:5-7.
PubMed

HANDLEY KF, Sood AK, Molin GZD, Westin SN, et al
Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
Gynecol Oncol. 2022;166:50-56.
PubMed Abstract available

MOKHTECH M, Gao SJ, Kassick M, Menderes G, et al
Declining use of inguinofemoral lymphadenectomy in the treatment of clinically negative, pathologic node positive vulvar cancer.
Gynecol Oncol. 2022;166:61-68.
PubMed Abstract available

O'CEARBHAILL RE, Perez-Fidalgo JA, Monk BJ, Tusquets I, et al
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Gynecol Oncol. 2022;166:36-43.
PubMed Abstract available

NELSON G
Social media in gynecologic oncology: A new frontier.
Gynecol Oncol. 2022;166:3-4.
PubMed

GEHRIG PA, Farley J
Introducing a new series in Gynecologic Oncology: Health equity in gynecologic oncology research.
Gynecol Oncol. 2022;166:1-2.
PubMed

CHERSTON C, Yoh K, Huang Y, Melamed A, et al
Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer.
Gynecol Oncol. 2022 Jul 1. pii: S0090-8258(22)00427.
PubMed Abstract available

June 2022

LIU K, Zhu Y, Zhou Y, Zhang Y, et al
Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00419.
PubMed Abstract available

MUNOZ JL, Blankenship LM, Ramsey PS, McCann GA, et al
Importance of the gynecologic oncologist in management of cesarean hysterectomy for Placenta Accreta Spectrum (PAS).
Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00429.
PubMed Abstract available

SY F, Greuel M, Winkler V, Bussmann H, et al
Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: A systematic review and meta-analysis.
Gynecol Oncol. 2022 Jun 30. pii: S0090-8258(22)00416.
PubMed Abstract available

WALL JA, Lipking K, Smith HJ, Huh WK, et al
Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
PubMed Abstract available

ROGOWSKI P, Rottler M, Walter F, Saicic S, et al
Clinical outcome of combined intracavitary / interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer.
Gynecol Oncol. 2022 Jun 25. pii: S0090-8258(22)00423.
PubMed Abstract available

BACORRO W, Baldivia K, Yu KK, Mariano J, et al
Outcomes with definitive radiotherapy among patients with locally advanced cervical cancer with relative or absolute contraindications to cisplatin: A systematic review and meta-analysis.
Gynecol Oncol. 2022 Jun 24. pii: S0090-8258(22)00422.
PubMed Abstract available

HEFFERNAN K, Nikitas FS, Shukla U, Camejo HS, et al
Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
Gynecol Oncol. 2022 Jun 22. pii: S0090-8258(22)00415.
PubMed Abstract available

DICKEN BJ, Billmire DF, Rich B, Hazard FK, et al
Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group.
Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00417.
PubMed Abstract available

RASMUSSEN CL, Thomsen LT, Baandrup L, Franzmann MB, et al
Changes in HPV prevalence in Danish women with vulvar cancer during 28 years - A nationwide study of >1300 cancer cases.
Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00418.
PubMed Abstract available

KEUNECKE C, Kulbe H, Dreher F, Taube ET, et al
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00414.
PubMed Abstract available

AO M, Zheng D, Wang J, Gu X, et al
Corrigendum to "Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia" [Gynecologic Oncology, Volume 162, Issue 3, September 2021, Pages 584-589].
Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00411.
PubMed

KIM NR, Lee AJ, Yang EJ, So KA, et al
Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.
Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00404.
PubMed Abstract available

BOGANI G, Di Donato V, Papadia A, Buda A, et al
Evaluating long-term outcomes of three approaches to retroperitoneal staging in endometrial cancer.
Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00407.
PubMed Abstract available

CAMPBELL R, Costa DSJ, Stockler MR, Lee YC, et al
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol. 2022 Jun 16. pii: S0090-8258(22)00335.
PubMed Abstract available

JERNIGAN A, Farley J, Walsh C
Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer.
Gynecol Oncol. 2022 Jun 15. pii: S0090-8258(22)00410.
PubMed

NAKAMURA K, Shigeyasu K, Okamoto K, Matsuoka H, et al
ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer.
Gynecol Oncol. 2022 Jun 10. pii: S0090-8258(22)00337.
PubMed Abstract available

HEALD B, Mokhtary S, Nielsen SM, Rojahn S, et al
Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00334.
PubMed Abstract available

SCHIFF JP, Mintz R, Cohen AC, Huang Y, et al
Overall survival in patients with FIGO stage IVA cervical cancer.
Gynecol Oncol. 2022 Jun 9. pii: S0090-8258(22)00333.
PubMed Abstract available

HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Gynecol Oncol. 2022 Jun 8. pii: S0090-8258(22)00331.
PubMed Abstract available

LOF P, van de Vrie R, Korse CM, van Gent MDJM, et al
Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?
Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00336.
PubMed Abstract available

ZHOU N, Cui Y, Zhu R, Kuang Y, et al
Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00306.
PubMed Abstract available

HORSBOL TA, Kjaer SK, Andersen EW, Ammitzboll G, et al
Use of hypnotics among women diagnosed with cervical cancer - A population-based cohort study.
Gynecol Oncol. 2022 Jun 6. pii: S0090-8258(22)00330.
PubMed Abstract available

NASIOUDIS D, Mastroyannis SA, Ko EM, Haggerty AF, et al
Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
Gynecol Oncol. 2022 Jun 3. pii: S0090-8258(22)00314.
PubMed Abstract available

DIGGS A, Sia TY, Huang Y, Gockley A, et al
Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
Gynecol Oncol. 2022 Jun 2. pii: S0090-8258(22)00329.
PubMed Abstract available

GERSHENSON DM, Sun CC, Westin SN, Eyada M, et al
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
Gynecol Oncol. 2022;165:560-567.
PubMed Abstract available

MARTIN AL, Sinha S, Peres LC, Hakam A, et al
The impact of distance to closest negative margin on survival after pelvic exenteration.
Gynecol Oncol. 2022;165:514-521.
PubMed Abstract available

SCHNACK TH, Froeding LP, Kristensen E, Niemann I, et al
Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study.
Gynecol Oncol. 2022;165:420-427.
PubMed Abstract available

HOU X, Zhai Y, Hu K, Liu CJ, et al
Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
Gynecol Oncol. 2022;165:552-559.
PubMed Abstract available

FELIX AS, Addison D
The intersection of gynecologic cancer, obesity, and cardiovascular disease.
Gynecol Oncol. 2022;165:403-404.
PubMed

NG AP, Sanaiha Y, Verma A, Lee C, et al
Insurance-based disparities and risk of financial toxicity among patients undergoing gynecologic cancer operations.
Gynecol Oncol. 2022 Jun 1. pii: S0090-8258(22)00328.
PubMed Abstract available

May 2022

YADAV G, Roque DM, Bellone S, Manavella DD, et al
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Gynecol Oncol. 2022 May 28. pii: S0090-8258(22)00332.
PubMed Abstract available

PIEDIMONTE S, Pond GR, Plante M, Nelson G, et al
Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study.
Gynecol Oncol. 2022 May 26. pii: S0090-8258(22)00310.
PubMed Abstract available

GORGEU V, Borghese B, Koual M, Just PA, et al
Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort.
Gynecol Oncol. 2022 May 25. pii: S0090-8258(22)00321.
PubMed Abstract available

NOLIN AC, Tian C, Hamilton CA, Casablanca Y, et al
Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning.
Gynecol Oncol. 2022 May 24. pii: S0090-8258(22)00312.
PubMed Abstract available

BROEKMAN KE, van der Aa MA, Nijman HW, Jalving M, et al
End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis.
Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00258.
PubMed Abstract available

GENNARI P, Tchaikovski S, Meszaros J, Gerken M, et al
Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer.
Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00313.
PubMed Abstract available

MAH SJ, Anpalagan T, Marcucci M, Eiriksson L, et al
The five-factor modified frailty index predicts adverse postoperative and chemotherapy outcomes in gynecologic oncology.
Gynecol Oncol. 2022 May 20. pii: S0090-8258(22)00311.
PubMed Abstract available

TYMON-ROSARIO JR, Manara P, Manavella DD, Bellone S, et al
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Gynecol Oncol. 2022 May 19. pii: S0090-8258(22)00305.
PubMed Abstract available

MARSH LA, Aviki EM, Wright JD, Chen L, et al
Sentinel lymph node mapping for endometrial cancer: Opportunity for medical waste reform.
Gynecol Oncol. 2022 May 18. pii: S0090-8258(22)00308.
PubMed Abstract available

ZHOU S, Liu S, Tian G, Zhao L, et al
KLK5 is associated with the radioresistance, aggression, and progression of cervical cancer.
Gynecol Oncol. 2022 May 17. pii: S0090-8258(22)00309.
PubMed Abstract available

WANG CC, Al-Rubaye R, Tran V, Montemorano L, et al
Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00307.
PubMed Abstract available

HINCHCLIFF E, Westin SN, Herzog TJ
State of the science: Contemporary front-line treatment of advanced ovarian cancer.
Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00275.
PubMed

ANGELES MA, Hernandez A, Perez-Benavente A, Cabarrou B, et al
The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
Gynecol Oncol. 2022 May 11. pii: S0090-8258(22)00278.
PubMed Abstract available

GUIDA F, Dioun S, Fagotti A, Melamed A, et al
Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
Gynecol Oncol. 2022 May 9. pii: S0090-8258(22)00218.
PubMed Abstract available

MCKINNISH TR, Greenwade MM, Wilkinson-Ryan I, Schwarz JK, et al
Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography.
Gynecol Oncol. 2022 May 7. pii: S0090-8258(22)00259.
PubMed Abstract available

DEMARI JA, Boyles GP, Barrington DA, Audrey Busho BS, et al
Less is more: Abdominal closure protocol does not reduce surgical site infection after hysterectomy.
Gynecol Oncol. 2022 May 4. pii: S0090-8258(22)00261.
PubMed Abstract available

STENZEL AE, Thomaier L, Jewett PI, Dona AC, et al
Interactions between physical activity and type of cancer treatment received on associations with psychosocial outcomes among gynecologic cancer survivors.
Gynecol Oncol. 2022 May 4. pii: S0090-8258(22)00260.
PubMed Abstract available

RONSINI C, Kohler C, De Franciscis P, La Verde M, et al
Laparo-assisted vaginal radical hysterectomy as a safe option for Minimal Invasive Surgery in early stage cervical cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2022 May 2. pii: S0090-8258(22)00251.
PubMed Abstract available

JAMIESON A, Thompson EF, Huvila J, Leung S, et al
Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases.
Gynecol Oncol. 2022;165:376-384.
PubMed Abstract available

MAXWELL GL, Secord AA, Powell MA
The ProMisE of uniform care for endometrial cancer patients.
Gynecol Oncol. 2022;165:199-200.
PubMed

KIM SK, Ursell P, Coleman RL, Monk BJ, et al
Mitigation and management strategies for ocular events associated with tisotumab vedotin.
Gynecol Oncol. 2022;165:385-392.
PubMed Abstract available

April 2022

THOMAS RJ, Provenzano D, Goyal S, Loew M, et al
Trends in guideline-adherent chemoradiation therapy for locally advanced cervical cancer before and after the affordable care act.
Gynecol Oncol. 2022 Apr 28. pii: S0090-8258(22)00256.
PubMed Abstract available

JACKSON CG, Moore KN, Cantrell L, Erickson BK, et al
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
Gynecol Oncol. 2022 Apr 28. pii: S0090-8258(22)00257.
PubMed Abstract available

WILHITE AM, Baca Y, Xiu J, Paladugu R, et al
Molecular profiles of endometrial cancer tumors among Black patients.
Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00255.
PubMed Abstract available

XU JY, Chen JN, Lei J, Hu M, et al
Local treatment improves survival in patients with stage IVB cervical cancer.
Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00254.
PubMed Abstract available

TANIGAWA T, Takeshima N, Ishikawa H, Nishio S, et al
Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
Gynecol Oncol. 2022 Apr 26. pii: S0090-8258(22)00252.
PubMed Abstract available

KARPEL HC, Chern JY, Smith J M, Smith A J, et al
Utility of germline multi-gene panel testing in patients with endometrial cancer.
Gynecol Oncol. 2022 Apr 25. pii: S0090-8258(22)00216.
PubMed Abstract available

FU Z, Taylor S, Modugno F
Lifetime ovulations and epithelial ovarian cancer risk and survival: A systematic review and meta-analysis.
Gynecol Oncol. 2022 Apr 23. pii: S0090-8258(22)00214.
PubMed Abstract available

WANG D, Jia S, Jia C, Cao D, et al
Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study.
Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00215.
PubMed Abstract available

MA X, Ren X, Ma F, Cai S, et al
Volumetric apparent diffusion coefficient (ADC) histogram metrics as imaging biomarkers for pretreatment predicting response to fertility-sparing treatment in patients with endometrial cancer.
Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00249.
PubMed Abstract available

BARRINGTON DA, Fox B, Meade C, Quick A, et al
Does the addition of radiation improve survival compared to chemotherapy alone in women with stage IV endometrial carcinoma? Analysis of the NCDB and SEER databases.
Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00248.
PubMed Abstract available

POTHURI B, Eskander RN, Randall LM, O'Malley DM, et al
Practice changing cervical cancer clinical trials.
Gynecol Oncol. 2022 Apr 20. pii: S0090-8258(22)00175.
PubMed

JOOYA ND, Ciccone MA, Brunette LL, Pham HQ, et al
Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer.
Gynecol Oncol. 2022 Apr 19. pii: S0090-8258(22)00203.
PubMed Abstract available

LUHRS O, Bollino M, Ekdahl L, Lonnerfors C, et al
Similar distribution of pelvic sentinel lymph nodes and nodal metastases in cervical and endometrial cancer. A prospective study based on lymphatic anatomy.
Gynecol Oncol. 2022 Apr 15. pii: S0090-8258(22)00209.
PubMed Abstract available

COUGHLIN SS, Datta B, Guha A, Wang X, et al
Cardiovascular conditions and obesity among gynecologic cancer survivors: Results from the 2020 behavioral risk factor surveillance system survey.
Gynecol Oncol. 2022 Apr 15. pii: S0090-8258(22)00207.
PubMed Abstract available

BARRINGTON DA, Riedinger C, Haight PJ, Tubbs C, et al
Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
Gynecol Oncol. 2022 Apr 11. pii: S0090-8258(22)00213.
PubMed Abstract available

LOF P, Retel VP, Algera MD, van Gent MDJM, et al
Clinical implementation of routine diagnostic laparoscopy to guide initial treatment in patients with advanced-stage epithelial ovarian cancer in Dutch clinical practice: Evaluation of support and a budget impact analysis.
Gynecol Oncol. 2022 Apr 9. pii: S0090-8258(22)00210.
PubMed Abstract available

SAPIENZA LG, Thomas JJ, Showalter TN, Echeverria AE, et al
Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal.
Gynecol Oncol. 2022 Apr 8. pii: S0090-8258(22)00208.
PubMed Abstract available

CHAMBERS LM, Chalif J, Vargas R
Analysis of patient experiences with gestational trophoblastic neoplasia reported on Instagram social media.
Gynecol Oncol. 2022 Apr 8. pii: S0090-8258(22)00211.
PubMed Abstract available

SON J, George GC, Nardo M, Krause KJ, et al
Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.
Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00195.
PubMed Abstract available

GERSEKOWSKI K, Delahunty R, Alsop K, Goode EL, et al
Germline BRCA variants, lifestyle and ovarian cancer survival.
Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00202.
PubMed Abstract available

SAND FL, Frederiksen K, Kjaer SK
Risk of recurrent disease following conization of cervical intraepithelial neoplasia grade 3 according to post-conization HPV status and surgical margins.
Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00197.
PubMed Abstract available

NORPPA N, Staff S, Helminen M, Auranen A, et al
Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.
Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00205.
PubMed Abstract available

BIZZARRI N, Marchetti C, Conte C, Loverro M, et al
The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00206.
PubMed Abstract available

SALVO G, Jhingran A, Ramalingam P, Legarreta AF, et al
Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: A NeCTuR study.
Gynecol Oncol. 2022 Apr 5. pii: S0090-8258(22)00204.
PubMed Abstract available

HENNO S, Jeanne C, Rouge TM, Genestie C, et al
Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).
Gynecol Oncol. 2022 Apr 4. pii: S0090-8258(22)00201.
PubMed Abstract available

POLTERAUER S, Reich O, Widschwendter A, Hadjari L, et al
Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial.
Gynecol Oncol. 2022;165:23-29.
PubMed Abstract available

PARPEX G, Bucau M, Estevez JP, Raimond E, et al
Impact of vulvar reconstruction on the accuracy of a nomogram for predicting local recurrence after surgery for vulvar cancer.
Gynecol Oncol. 2022;165:143-148.
PubMed Abstract available

RAMOS MM, Maesta I, de Araujo Costa RA, Mazeto GMFS, et al
Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism.
Gynecol Oncol. 2022;165:137-142.
PubMed Abstract available

LIAO X, Xia X, Su W, Yan H, et al
Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma.
Gynecol Oncol. 2022;165:105-113.
PubMed Abstract available

YAZDANFARD NW, Mikkelsen LH, Behrendt N, Fuglsang K, et al
Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival.
Gynecol Oncol. 2022;165:53-59.
PubMed Abstract available

VAN DER PLOEG P, Uittenboogaard A, Bosch SL, van Diest PJ, et al
Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium.
Gynecol Oncol. 2022;165:114-120.
PubMed Abstract available

KASHOFER K, Regauer S, Reich O, Petru E, et al
Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance.
Gynecol Oncol. 2022;165:121-128.
PubMed Abstract available

March 2022

SCHIFF JP, Mahmood M, Huang Y, Powell MA, et al
The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies.
Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00199.
PubMed Abstract available

MARINELLI LM, Kisiel JB, Slettedahl SW, Mahoney DW, et al
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00200.
PubMed Abstract available

SIMILA-MAARALA J, Soovares P, Pasanen A, Ahvenainen T, et al
TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00198.
PubMed Abstract available

LIM H, In Shim J, Park SJ, Noh J, et al
Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
Gynecol Oncol. 2022 Mar 30. pii: S0090-8258(22)00196.
PubMed Abstract available

MOHAMUD A, Hogdall C, Schnack T
Prognostic value of the 2018 FIGO staging system for cervical cancer.
Gynecol Oncol. 2022 Mar 25. pii: S0090-8258(22)00127.
PubMed Abstract available

PERRONE E, De Felice F, Capasso I, Distefano E, et al
The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method.
Gynecol Oncol. 2022 Mar 24. pii: S0090-8258(22)00180.
PubMed Abstract available

ZHANG L, Gu W, Zhang L, Miao R, et al
The effects of a nurse-led couples intervention on marital quality of couples with gynecological cancer: A clinical randomized controlled trial.
Gynecol Oncol. 2022 Mar 23. pii: S0090-8258(22)00181.
PubMed Abstract available

STELTEN S, van Lonkhuijzen LRCW, Hartman YAW, van Driel WJ, et al
Experiences, adherence and satisfaction with a combined exercise and dietary intervention for patients with ovarian cancer undergoing chemotherapy: A mixed-methods study.
Gynecol Oncol. 2022 Mar 22. pii: S0090-8258(22)00182.
PubMed Abstract available

DAIX M, Martinez Gomez C, Angeles MA, Tock S, et al
Extended pelvic resection for gynecological malignancies: A review of out-of-the-box surgery.
Gynecol Oncol. 2022 Mar 21. pii: S0090-8258(22)00174.
PubMed Abstract available

VARGIU V, Rosati A, Capozzi VA, Sozzi G, et al
Impact of Obesity on Sentinel Lymph Node Mapping in Patients with apparent Early-Stage Endometrial Cancer: The ObeLyX study.
Gynecol Oncol. 2022 Mar 18. pii: S0090-8258(22)00173.
PubMed Abstract available

ARGENTA PA, Mattson J, Rivard CL, Luther E, et al
Robot-assisted versus laparoscopic minimally invasive surgery for the treatment of stage I endometrial cancer.
Gynecol Oncol. 2022 Mar 18. pii: S0090-8258(22)00178.
PubMed Abstract available

KULKARNI A, Sun G, Manuppelli S, Mendez H, et al
Sexual health and function among patients receiving systemic therapy for primary gynecologic cancers.
Gynecol Oncol. 2022 Mar 17. pii: S0090-8258(22)00179.
PubMed Abstract available

SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
Gynecol Oncol. 2022 Mar 16. pii: S0090-8258(22)00176.
PubMed Abstract available

HACK AP, Zweemer RP, Jonges TN, van der Leij F, et al
Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study.
Gynecol Oncol. 2022 Mar 14. pii: S0090-8258(22)00177.
PubMed Abstract available

MOUKARZEL LA, Ferrando L, Dopeso H, Stylianou A, et al
Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
Gynecol Oncol. 2022 Mar 12. pii: S0090-8258(22)00141.
PubMed Abstract available

POST CCB, Westermann AM, Boere IA, Witteveen PO, et al
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
Gynecol Oncol. 2022 Mar 11. pii: S0090-8258(22)00145.
PubMed Abstract available

SIEGENTHALER F, Lindemann K, Epstein E, Rau TT, et al
Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.
Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00143.
PubMed Abstract available

HAWKINS GM, Burkett WC, McCoy AN, Nichols HB, et al
Differences in the microbial profiles of early stage endometrial cancers between Black and White women.
Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00142.
PubMed Abstract available

KIM J, Noh JJ, Lee TK, Kim SI, et al
Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea.
Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00140.
PubMed Abstract available

MATSUO K, Klar M, Khetan VU, Vallejo A, et al
Uptake in sentinel lymph node biopsy for endometrial cancer with T3 classification.
Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00144.
PubMed Abstract available

CHALIF J, Yao M, Gruner M, Kuznicki M, et al
Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00065.
PubMed Abstract available

SCHNARR KL, Seow H, Pond GR, Helpman L, et al
The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers.
Gynecol Oncol. 2022 Mar 2. pii: S0090-8258(22)00129.
PubMed Abstract available

LEITAO MM JR
The end of routine lymphadenectomy for the treatment of cervical cancer is rapidly approaching.
Gynecol Oncol. 2022;164:461-462.
PubMed

JAMIESON A, Huvila J, Thompson EF, Leung S, et al
Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification.
Gynecol Oncol. 2022 Mar 1. pii: S0090-8258(22)00085.
PubMed Abstract available

BRUNETTE LL, Khetan VU, Deshpande RR, Nusbaum DJ, et al
Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States.
Gynecol Oncol. 2022;164:651-657.
PubMed Abstract available

SCHLEISS-ANDREASSEN JL, Kristensen E, Froding LP, Staehr E, et al
Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma.
Gynecol Oncol. 2022;164:543-549.
PubMed Abstract available

February 2022

GOINS EC, Weber JM, Truong T, Moss HA, et al
Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.
Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00069.
PubMed Abstract available

PH M, Maulard A, Scherier S, Sanson C, et al
Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review.
Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00051.
PubMed Abstract available

MATSUO K, Khetan VU, Brunette LL, Jooya ND, et al
Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer.
Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00125.
PubMed Abstract available

ZAMMARRELLI WA 3RD, Greenman M, Rios-Doria E, Miller K, et al
Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma.
Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00122.
PubMed Abstract available

FALCONE F, Malzoni M, Carnelli M, Cormio G, et al
Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00128.
PubMed Abstract available

MATSUO K, Chen L, Guo XM, Roman LD, et al
Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study.
Gynecol Oncol. 2022 Feb 25. pii: S0090-8258(22)00126.
PubMed Abstract available

KOBAYASHI E, Nakatani E, Tanaka T, Yosuke K, et al
Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081.
Gynecol Oncol. 2022 Feb 24. pii: S0090-8258(22)00089.
PubMed Abstract available

MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00124.
PubMed

BAETEN IGT, Hoogendam JP, Jonges GN, Jurgenliemk-Schulz IM, et al
Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer.
Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00121.
PubMed Abstract available

ALGERA MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, et al
Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00123.
PubMed Abstract available

KIM YN, Kim JC, Chung YS, Park J, et al
Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study.
Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00091.
PubMed Abstract available

ANDERSON EM, Luu M, Lu DJ, Chung EM, et al
Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer.
Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00024.
PubMed Abstract available

LAFARGUE CJ, Handley KF, Fleming ND, Nick AM, et al
Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00090.
PubMed Abstract available

HUANG Y, Hou JY, Melamed A, St Clair CM, et al
Pathologic characteristics, patterns of care, and outcomes of Asian-Americans and Pacific islanders with uterine cancer.
Gynecol Oncol. 2022 Feb 16. pii: S0090-8258(22)00088.
PubMed Abstract available

VANDERSTICHELE A, Loverix L, Busschaert P, Van Nieuwenhuysen E, et al
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
Gynecol Oncol. 2022 Feb 14. pii: S0090-8258(22)00073.
PubMed Abstract available

DHOLAKIA J, Liang MI, Aviki EM
Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies.
Gynecol Oncol. 2022 Feb 12. pii: S0090-8258(22)00087.
PubMed

PARK J, Kim SI, Jeong SY, Kim Y, et al
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Gynecol Oncol. 2022 Feb 10. pii: S0090-8258(22)00086.
PubMed Abstract available

YAHATA H, Kodama K, Okugawa K, Hachisuga K, et al
Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer.
Gynecol Oncol. 2022 Feb 9. pii: S0090-8258(22)00070.
PubMed Abstract available

KRAUS EJ, Nicosia B, Shalowitz DI
A qualitative study of patients' attitudes towards telemedicine for gynecologic cancer care.
Gynecol Oncol. 2022 Feb 8. pii: S0090-8258(22)00074.
PubMed Abstract available

WAGAR MK, Mojdehbakhsh RP, Godecker A, Rice LW, et al
Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
Gynecol Oncol. 2022 Feb 7. pii: S0090-8258(22)00071.
PubMed Abstract available

LEMON LS, Orr B, Modugno F, Buckanovich RJ, et al
Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?
Gynecol Oncol. 2022 Feb 6. pii: S0090-8258(22)00049.
PubMed Abstract available

JOLY F, Fabbro M, Follana P, Lequesne J, et al
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Gynecol Oncol. 2022 Feb 2. pii: S0090-8258(22)00048.
PubMed Abstract available

SWIFT BE, Tigert M, Nica A, Covens A, et al
The accuracy of intraoperative frozen section examination of sentinel lymph nodes in squamous cell cancer of the vulva.
Gynecol Oncol. 2022;164:393-397.
PubMed Abstract available

SHIN DW, Bae J, Ha J, Lee WM, et al
Trends in incidence and survival of patients with vulvar cancer in an Asian country: Analysis of the Korean Central Cancer Registry 1999-2018.
Gynecol Oncol. 2022;164:386-392.
PubMed Abstract available

January 2022

TRILLSCH F, Mahner S, Ataseven B, Asher R, et al
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00050.
PubMed Abstract available

LICHTER KE, Levinson K, Hammer A, Lippitt MH, et al
Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States.
Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00025.
PubMed Abstract available

RAIMONDO D, Raffone A, Zakhari A, Maletta M, et al
The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: A systematic review and meta-analysis.
Gynecol Oncol. 2022 Jan 25. pii: S0090-8258(22)00046.
PubMed Abstract available

WU X, Keller EJ, Rabei R, Rockwell H, et al
Cost-effectiveness of tunneled peritoneal catheters versus repeat paracenteses for recurrent ascites in gynecologic malignancies.
Gynecol Oncol. 2022 Jan 24. pii: S0090-8258(22)00019.
PubMed Abstract available

RAFFONE A, Travaglino A, Raimondo D, Neola D, et al
Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature.
Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00020.
PubMed Abstract available

WATSON CH, Monuszko K, Freeman S, Kurtovic K, et al
Reducing non-surgical readmissions on a gynecologic oncology service.
Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00005.
PubMed Abstract available

LEON-CASTILLO A, Horeweg N, Peters EEM, Rutten T, et al
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Gynecol Oncol. 2022 Jan 22. pii: S0090-8258(22)00007.
PubMed Abstract available

COLOMBO N, Tomao F, Benedetti Panici P, Nicoletto MO, et al
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00023.
PubMed Abstract available

XIA YY, Gronwald J, Karlan B, Lubinski J, et al
Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00022.
PubMed Abstract available

BOGANI G, Ray-Coquard I, Concin N, Ngoi NYL, et al
Clear cell carcinoma of the endometrium.
Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00021.
PubMed Abstract available

SLOMOVITZ BM, Filiaci VL, Walker JL, Taub MC, et al
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01699.
PubMed Abstract available

BOUCHARD-FORTIER G, Gien LT, Sutradhar R, Chan WC, et al
Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study.
Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00004.
PubMed Abstract available

POVEDA A, Lheureux S, Colombo N, Cibula D, et al
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01693.
PubMed Abstract available

ZHANG J, Yu S, Li Q, Wang Q, et al
Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.
Gynecol Oncol. 2022 Jan 15. pii: S0090-8258(22)00018.
PubMed Abstract available

FIEGL H, Hagenbuchner J, Kyvelidou C, Seeber B, et al
Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.
Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00009.
PubMed Abstract available

BEINSE G, Le Frere Belda MA, Just PA, Bekmezian N, et al
Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer.
Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00006.
PubMed Abstract available

YAN L, Liu Y, Zhang J, Chen X, et al
In vivo and in vitro study of the potential hazards of surgical smoke during cervical cancer treatment with an ultrasonic scalpel.
Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00008.
PubMed Abstract available

ALTIN D, Taskin S, Ortac F, Tokgozoglu N, et al
Diagnostic accuracy of sentinel node biopsy in non-endometrioid, high-grade and/or deep myoinvasive endometrial cancer: A Turkish gynecologic oncology group study (TRSGO-SLN-006).
Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00003.
PubMed Abstract available

MUSA FB, Brouwer E, Ting J, Schwartz NRM, et al
Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.
Gynecol Oncol. 2022 Jan 11. pii: S0090-8258(21)01696.
PubMed Abstract available

REID HW, Broadwater G, Montes de Oca MK, Selvan B, et al
Distress screening in endometrial cancer leads to disparity in referral to support services.
Gynecol Oncol. 2022 Jan 8. pii: S0090-8258(22)00001.
PubMed Abstract available

TEMKIN SM, Chapman-Davis E, Nair N, Cohn DE, et al
Creating work environments where people of all genders in gynecologic oncology can thrive: An SGO evidence-based review.
Gynecol Oncol. 2022 Jan 6. pii: S0090-8258(21)01700.
PubMed Abstract available

AMPOFO AG, Boyes AW, Khumalo PG, Mackenzie L, et al
Improving knowledge, attitudes, and uptake of cervical cancer prevention among female students: A systematic review and meta-analysis of school-based health education.
Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01680.
PubMed Abstract available

WEINMANN S, Phillips S, Sweet K, Cosgrove CM, et al
Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01695.
PubMed Abstract available

LIN DI, Fine A, Danziger NA, Huang RSP, et al
Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01698.
PubMed Abstract available

WANG J, Dong J, Zhou Y, Wang K, et al
Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.
Gynecol Oncol. 2022 Jan 4. pii: S0090-8258(21)01701.
PubMed Abstract available

SHALOWITZ DI, DeMari JA
Defining the essential role of the gynecologic oncologist in rural ovarian cancer care delivery.
Gynecol Oncol. 2022;164:1-2.
PubMed

WOELBER L, Prieske K, Eulenburg CZ, Corradini S, et al
Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study.
Gynecol Oncol. 2022;164:68-75.
PubMed Abstract available

BORCINOVA M, Ragosch V, Jarkovsky J, Bajsova S, et al
Challenges in lower limb lymphoedema assessment based on limb volume change: Lessons learnt from the SENTIX prospective multicentre study.
Gynecol Oncol. 2022;164:76-84.
PubMed Abstract available

December 2021

EKDAHL L, Paraghamian S, Eoh KJ, Thumuluru KM, et al
Long term oncologic and reproductive outcomes after robot-assisted radical trachelectomy for early-stage cervical cancer. An international multicenter study.
Gynecol Oncol. 2021 Dec 31. pii: S0090-8258(21)01697.
PubMed Abstract available

CORRIGAN KL, Yoder A, De B, Lin L, et al
Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis.
Gynecol Oncol. 2021 Dec 30. pii: S0090-8258(21)01690.
PubMed Abstract available

SPONHOLTZ SE, Ezendam NPM, de Rooij BH, Parner E, et al
SENTIREC - The sentinel node mapping in women with cervical cancer study - Patient-reported early lymphedema and its impact on quality of life.
Gynecol Oncol. 2021 Dec 29. pii: S0090-8258(21)01692.
PubMed Abstract available

KIM SI, Choi BR, Kim HS, Chung HH, et al
Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach.
Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01691.
PubMed Abstract available

LIGHTFOOT MDS, Felix AS, Bishop EE, Henderson AP, et al
Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomy.
Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01636.
PubMed Abstract available

THELISSEN AAB, Jurgenliemk-Schulz IM, van der Leij F, Peters M, et al
Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2021 Dec 27. pii: S0090-8258(21)01694.
PubMed Abstract available

BEESLEY VL, Ross TL, King MT, Campbell R, et al
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01632.
PubMed Abstract available

REIJNTJES B, van Suijlichem M, Woolderink JM, Bongers MY, et al
Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial.
Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01676.
PubMed Abstract available

CIBULA D, Dostalek L, Jarkovsky J, Mom CH, et al
Post-recurrence survival in patients with cervical cancer.
Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01675.
PubMed Abstract available

PHILP L, Alimena S, Ferris W, Saini A, et al
Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
Gynecol Oncol. 2021 Dec 22. pii: S0090-8258(21)01674.
PubMed Abstract available

HARTER P, Mouret-Reynier MA, Pignata S, Cropet C, et al
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01673.
PubMed Abstract available

MONK BJ, Smith G, Lima J, Long GH, et al
Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01634.
PubMed Abstract available

KO EM, Bekelman JE, Hicks-Courant K, Brensinger CM, et al
Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01627.
PubMed Abstract available

GUANI B, Mahiou K, Crestani A, Cibula D, et al
Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis.
Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01672.
PubMed Abstract available

AGHAJANIAN C, Swisher EM, Okamoto A, Steffensen KD, et al
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Gynecol Oncol. 2021 Dec 17. pii: S0090-8258(21)01638.
PubMed Abstract available

HA HI, Park EY, Eoh KJ, Lee YJ, et al
Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
Gynecol Oncol. 2021 Dec 16. pii: S0090-8258(21)01639.
PubMed Abstract available

DAVIDSON BA, Puechl AM, Watson CH, Lim S, et al
Promoting timely goals of care conversations between gynecologic cancer patients at high-risk of death and their providers.
Gynecol Oncol. 2021 Dec 15. pii: S0090-8258(21)01635.
PubMed Abstract available

SWIFT BE, Maeda A, Bouchard-Fortier G
Low incidence of venous thromboembolism after gynecologic oncology surgery: Who is at greatest risk?
Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01637.
PubMed Abstract available

SHI Y, Chen J, Shi B, Liu A, et al
Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01633.
PubMed Abstract available

ZHOU ZN, Chen L, Melamed A, St Clair CM, et al
Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer.
Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01631.
PubMed Abstract available

DEBOER RJ, Umutoni V, Bazzett-Matabele L, Katznelson E, et al
Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.
Gynecol Oncol. 2021 Dec 13. pii: S0090-8258(21)01628.
PubMed Abstract available

SWISHER EM, Aghajanian C, O'Malley DM, Fleming GF, et al
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Gynecol Oncol. 2021 Dec 11. pii: S0090-8258(21)01630.
PubMed Abstract available

MATULONIS UA, Huang HQ, Filiaci VL, Randall M, et al
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
Gynecol Oncol. 2021 Dec 10. pii: S0090-8258(21)01625.
PubMed Abstract available

NICA A, Sutradhar R, Kupets R, Covens A, et al
Pre-operative wait times in high-grade non-endometrioid endometrial cancer: Do surgical delays impact patient survival?
Gynecol Oncol. 2021 Dec 9. pii: S0090-8258(21)01621.
PubMed Abstract available

LARA OD, Smith M, Wang Y, O'Cearbhaill RE, et al
COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic.
Gynecol Oncol. 2021 Dec 7. pii: S0090-8258(21)01629.
PubMed Abstract available

KORENAGA TK, Yoshida EJ, Pierson W, Chang J, et al
Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.
Gynecol Oncol. 2021 Dec 2. pii: S0090-8258(21)01608.
PubMed Abstract available

WEI JJ
Linking altered microRNA expression to racial disparities in uterine serous carcinoma.
Gynecol Oncol. 2021;163:446-447.
PubMed

HODGSON DR, Brown JS, Dearden SP, Lai Z, et al
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
Gynecol Oncol. 2021;163:563-568.
PubMed Abstract available

November 2021

JOHN CS, Fong A, Alban R, Gillen J, et al
Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01521.
PubMed Abstract available

DOLL KM, Nguyen A, Alson JG
A conceptual model of vulnerability to care delay among women at risk for endometrial cancer.
Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01603.
PubMed Abstract available

DUPONT NC, Enserro D, Brady MF, Moxley K, et al
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol. 2021 Nov 29. pii: S0090-8258(21)01607.
PubMed Abstract available

MANZOUR N, Nunez-Cordoba JM, Chiva L, Chacon E, et al
Pattern of relapse in patients with stage IB1 cervical cancer after radical hysterectomy as primary treatment. Minimally invasive surgery vs. open approach. Systematic review and meta-analysis.
Gynecol Oncol. 2021 Nov 27. pii: S0090-8258(21)01623.
PubMed Abstract available

MOYA-ALARCON C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, et al
Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01604.
PubMed Abstract available

CIANCI S, Fedele C, Vizzielli G, Pasciuto T, et al
Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON.
Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01605.
PubMed Abstract available

ARYASOMAYAJULA C, Chanana A, Tandel M, Kwan L, et al
The role of high-risk HPV testing in cervical cancer surveillance.
Gynecol Oncol. 2021 Nov 23. pii: S0090-8258(21)01606.
PubMed Abstract available

RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693].
Gynecol Oncol. 2021 Nov 19. pii: S0090-8258(21)01601.
PubMed

NJOKU K, Ramchander NC, Wan YL, Barr CE, et al
Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis.
Gynecol Oncol. 2021 Nov 18. pii: S0090-8258(21)01602.
PubMed Abstract available

MATUSZEWSKA K, Ten Kortenaar S, Pereira M, Santry LA, et al
Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01599.
PubMed Abstract available

HUANG J, Deng Y, Boakye D, Tin MS, et al
Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis.
Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01598.
PubMed Abstract available

LADBURY C, Li R, Shiao J, Liu J, et al
Characterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging?
Gynecol Oncol. 2021 Nov 15. pii: S0090-8258(21)01600.
PubMed Abstract available

MATTHEWS BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, et al
Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
Gynecol Oncol. 2021 Nov 13. pii: S0090-8258(21)01553.
PubMed Abstract available

WEEKS KS, Lynch CF, West M, Carnahan R, et al
Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01555.
PubMed Abstract available

KHOJA L, Weber RP, Webb PM, Jordan SJ, et al
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01552.
PubMed Abstract available

FABER MT, Horsbol TA, Baandrup L, Dalton SO, et al
Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996-2017.
Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01554.
PubMed Abstract available

PRAISS AM, Huang Y, St Clair CM, Melamed A, et al
Long-term outcomes of vaginal hysterectomy for endometrial cancer.
Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01526.
PubMed Abstract available

SISODIA RC, Alimena S, Ferris W, Saini A, et al
Initial findings from a prospective, large scale patient reported outcomes program in patients with gynecologic malignancy.
Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01528.
PubMed Abstract available

MANNING-GEIST BL, Gordhandas SB, Giri DD, Iasonos A, et al
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01551.
PubMed Abstract available

ORELLANA TJ, Kim H, Beriwal S, Bhargava R, et al
Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer.
Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01515.
PubMed Abstract available

MENG Y, Chu T, Lin S, Wu P, et al
Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study.
Gynecol Oncol. 2021 Nov 2. pii: S0090-8258(21)01451.
PubMed Abstract available

ALHILLI MM, Arend RC
International gynecologic cancer society (IGCS) 2021 meeting report.
Gynecol Oncol. 2021 Nov 1. pii: S0090-8258(21)01548.
PubMed

HINCHCLIFF EM, Westin SN
Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls.
Gynecol Oncol. 2021;163:217-219.
PubMed

SACCARDI C, Zovato S, Spagnol G, Bonaldo G, et al
Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
Gynecol Oncol. 2021;163:364-370.
PubMed Abstract available

October 2021

MATSUO K, Klar M, Khetan VU, Violette CJ, et al
Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States.
Gynecol Oncol. 2021 Oct 30. pii: S0090-8258(21)01529.
PubMed Abstract available

ROCCONI RP, Wilhite AM, Schambeau L, Scalici J, et al
A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01527.
PubMed Abstract available

CALO CA, Smith BQ, Dorayappan KDP, Saini U, et al
Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01520.
PubMed Abstract available

WARRING SK, Borah B, Moriarty J, Gullerud R, et al
The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup.
Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01523.
PubMed Abstract available

GOLDBERG RM, Kim SR, Fazelzad R, Li X, et al
Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01524.
PubMed Abstract available

EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01525.
PubMed Abstract available

CHARGARI C, Arbyn M, Leary A, Abu-Rustum NR, et al
Increasing global accessibility to high-level treatments for cervical cancers.
Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01517.
PubMed Abstract available

SOOVARES P, Pasanen A, Simila-Maarala J, Butzow R, et al
Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
Gynecol Oncol. 2021 Oct 25. pii: S0090-8258(21)01522.
PubMed Abstract available

WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
PubMed Abstract available

WITJES VM, van Bommel MHD, Ligtenberg MJL, Vos JR, et al
Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01516.
PubMed Abstract available

BALAYA V, Guani B, Morice P, Querleu D, et al
Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: A post-hoc analysis of SENTICOL I and SENTICOL II cohorts.
Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01518.
PubMed Abstract available

SHIN W, Park SY, Seo SS, Lim MC, et al
Predicting the risk of the distant recurrence of cervical cancer after concurrent chemoradiation: A validation study of the Korean Gynecologic Oncologic Group (KGOG)-1024 model.
Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01514.
PubMed Abstract available

TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
PubMed Abstract available

GUDGEON JM, Wallentine JC, Bonham EM, McLaughlin HD, et al
Determination of test performance of two contemporary screening tests for Lynch syndrome in endometrial cancer: A clinical trial.
Gynecol Oncol. 2021 Oct 21. pii: S0090-8258(21)01401.
PubMed Abstract available

HE WQ, Li C
Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends.
Gynecol Oncol. 2021 Oct 20. pii: S0090-8258(21)01519.
PubMed Abstract available

HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
PubMed

HOROWITZ NS, Eskander RN, Adelman MR, Burke W, et al
Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation.
Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01421.
PubMed

MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
PubMed Abstract available

MARTIN A, Wells A, Anderson ML, Chern JY, et al
Trends in ureteral surgery on an academic gynecologic oncology service.
Gynecol Oncol. 2021 Oct 18. pii: S0090-8258(21)01453.
PubMed Abstract available

THOMAIER L, Darst BF, Jewett P, Hoffmann C, et al
Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
Gynecol Oncol. 2021 Oct 18. pii: S0090-8258(21)01450.
PubMed Abstract available

LEVINSON K, Beavis AL, Purdy C, Rositch AF, et al
Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538].
Gynecol Oncol. 2021 Oct 12. pii: S0090-8258(21)01386.
PubMed

GERNIER F, Gompel A, Rousset-Jablonski C, Kalbacher E, et al
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
Gynecol Oncol. 2021 Oct 11. pii: S0090-8258(21)01419.
PubMed Abstract available

KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
PubMed Abstract available

LIU J, Burris H, Wang JS, Barroilhet L, et al
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
PubMed Abstract available

EDMONDSON RJ, O'Connell RL, Banerjee S, Mileshkin L, et al
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Gynecol Oncol. 2021 Oct 5. pii: S0090-8258(21)01379.
PubMed Abstract available

SHAH PD, Wethington SL, Pagan C, Latif N, et al
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Gynecol Oncol. 2021 Oct 4. pii: S0090-8258(21)01322.
PubMed Abstract available

ALHILLI MM, Rybicki L, Carr C, Yao M, et al
Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01377.
PubMed Abstract available

LEE L, Howitt B, Cheng T, King M, et al
MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma.
Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01384.
PubMed Abstract available

TEWARIE NMSB, van Driel WJ, van Ham M, Wouters MW, et al
Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01392.
PubMed

CLAIR KH, Bristow RE
The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
Gynecol Oncol. 2021;163:3-4.
PubMed

VAN TRIEST B, Rasing M, van der Velden J, de Hullu J, et al
Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study.
Gynecol Oncol. 2021;163:117-124.
PubMed Abstract available

September 2021

SWISHER EM, Kristeleit RS, Oza AM, Tinker AV, et al
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01329.
PubMed Abstract available

AZZALINI E, Barbazza R, Stanta G, Giorda G, et al
Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01382.
PubMed Abstract available

HOEIJMAKERS YM, Eysbouts YK, Massuger LFAG, Dandis R, et al
Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01385.
PubMed Abstract available

LI JY, Park HS, Huang GS, Young MR, et al
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01391.
PubMed Abstract available

HA HI, Cho SH, Lim J, Lee YJ, et al
Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01383.
PubMed Abstract available

LANDY R, Mathews C, Robertson M, Wiggins CL, et al
Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353].
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01393.
PubMed

BRYK S, Katuwal S, Haltia UM, Tapper J, et al
Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.
Gynecol Oncol. 2021 Sep 28. pii: S0090-8258(21)01381.
PubMed Abstract available

VAN DER PLAS RCJ, Bos AME, Jurgenliemk-Schulz IM, Gerestein CG, et al
Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes.
Gynecol Oncol. 2021 Sep 25. pii: S0090-8258(21)01334.
PubMed Abstract available

ATASEVEN B, Tripon D, Schwameis R, Harter P, et al
Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01335.
PubMed Abstract available

RESHKO LB, Gaskins JT, Rattani A, Farley AA, et al
Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.
Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01375.
PubMed Abstract available

CONTOS G, Baca Y, Xiu J, Brown J, et al
Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
Gynecol Oncol. 2021 Sep 22. pii: S0090-8258(21)01380.
PubMed Abstract available

JOU J, Charo L, Hom-Tedla M, Coakley K, et al
Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer.
Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01374.
PubMed Abstract available

LEE SJ, Kim YH, Lee MY, Ko HS, et al
Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women.
Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01376.
PubMed Abstract available

AO M, Zheng D, Wang J, Gu X, et al
Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia.
Gynecol Oncol. 2021;162:584-589.
PubMed Abstract available

GWACHAM NI, McKenzie ND, Fitzgerald ER, Ahmad S, et al
Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives.
Gynecol Oncol. 2021;162:809-815.
PubMed Abstract available

August 2021

SALANI R, Liu JF
The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts.
Gynecol Oncol. 2021;162:245-248.
PubMed

GROENEWEG JW, Roze JF, Peters EDJ, Sereno F, et al
FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Gynecol Oncol. 2021;162:413-420.
PubMed Abstract available

KELTTO N, Leivonen A, Pankakoski M, Sarkeala T, et al
Cervical testing beyond the screening target age - A register-based cohort study from Finland.
Gynecol Oncol. 2021;162:315-321.
PubMed Abstract available

July 2021

CUZICK J, Du R, Adcock R, Kinney W, et al
Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.
Gynecol Oncol. 2021 Jul 9. pii: S0090-8258(21)00525.
PubMed Abstract available

SALVADO A, Miralpeix E, Sole-Sedeno JM, Kanjou N, et al
Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: Cytology and HPV genotyping.
Gynecol Oncol. 2021 Jul 2. pii: S0090-8258(21)00515.
PubMed Abstract available

June 2021

CHATZISTAMATIOU K, Tsertanidou A, Moysiadis T, Mouchtaropoulou E, et al
Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
Gynecol Oncol. 2021 Jun 28. pii: S0090-8258(21)00516.
PubMed Abstract available

VAN KEER S, Peeters E, Vanden Broeck D, De Sutter P, et al
Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol.
Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00490.
PubMed Abstract available

PEI X, Xiang L, Chen W, Jiang W, et al
The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix.
Gynecol Oncol. 2021;161:779-786.
PubMed Abstract available

CHIAPPA V, Interlenghi M, Salvatore C, Bertolina F, et al
Using rADioMIcs and machine learning with ultrasonography for the differential diagnosis of myometRiAL tumors (the ADMIRAL pilot study). Radiomics and differential diagnosis of myometrial tumors.
Gynecol Oncol. 2021;161:838-844.
PubMed Abstract available

SEZEN D, Patel RR, Tang C, Onstad M, et al
Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma.
Gynecol Oncol. 2021;161:645-652.
PubMed Abstract available

ZACH D, Avall-Lundqvist E, Falconer H, Hellman K, et al
Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study.
Gynecol Oncol. 2021;161:748-754.
PubMed Abstract available

May 2021

PRIESKE K, Woelber L, Muallem MZ, Eulenburg C, et al
Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study.
Gynecol Oncol. 2021;161:442-448.
PubMed Abstract available

BOHLIN KS, Bruno AK, von Knorring C, Rahm C, et al
Accuracy of computerized tomography in the preoperative evaluation of metastases in primary vulvar cancer - A population-based study.
Gynecol Oncol. 2021;161:449-453.
PubMed Abstract available

KOUAL M, Benoit L, Nguyen-Xuan HT, Bentivegna E, et al
Diagnostic value of indocyanine green fluorescence guided sentinel lymph node biopsy in vulvar cancer: A systematic review.
Gynecol Oncol. 2021;161:436-441.
PubMed Abstract available

GILLEN J, Miller A, Bell-McGuinn KM, Schilder RJ, et al
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gynecol Oncol. 2021;161:512-515.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: